Final Version COLLABORATIVE RESEARCH AGREEMENT between EPIX and SCHERING
EXHIBIT 10.2
CONFIDENTIAL TREATMENT
EPIX Medical, Inc. has requested that the marked portions of this document be accorded confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.
Final Version
COLLABORATIVE RESEARCH AGREEMENT
between
EPIX
and
SCHERING
TABLE OF CONTENTS
|
|
|
|
|
||||
|
|
|
|
|
||||
|
|
|||||||
|
|
|||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|||||||
|
|
|||||||
|
|
|
|
|
||||
|
|
|
||||||
|
|
|||||||
|
|
|||||||
|
|
|
|
|
||||
|
OPTION RIGHTS FOR DEVELOPMENT CANDIDATES AND JOINT TECHNOLOGY |
|||||||
|
|
|
||||||
|
|
|||||||
|
|
|
||||||
|
|
|
||||||
|
|
|||||||
|
|
|||||||
|
|
|||||||
|
|
|
|
|
||||
|
|
|
|
|
||||
|
|
|||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
|
|
|
||||||
i
|
|
||||
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
||||
|
|
|
|||
|
|
|
|||
|
|
||||
|
|
||||
|
|
||||
|
|
|
|
||
|
|||||
|
|
|
|
|
|
|
|
||||
|
|
|
|||
|
|
|
|||
|
|
||||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
||||
|
|
|
|||
|
|
|
|||
|
|
||||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
||||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
|
||||
|
|
|
||||
|
|
|||||
|
|
|||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|||||
|
|
|||||
|
|
|
|
|||
|
|
|
|
|
||
|
|
|||||
ii
|
|
|||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|||
|
|
|||
|
|
|
Patent Filing, Prosecution and Maintenance of Joint Patent Rights |
|
|
|
|
||
|
|
|
||
|
|
|||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|||
|
|
|
|
|
|
|
|
||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|
||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
iii
|
|
||||
|
|
|
|||
|
|
|
|||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
|
|
|
|
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
Exhibit 3.2A |
|
Copy of Loan Agreement |
|
|
|
Exhibit 3.2B |
|
Copy of Security Agreement |
|
iv
COLLABORATIVE RESEARCH AGREEMENT
This COLLABORATIVE RESEARCH AGREEMENT (this “Agreement”) is entered into as of May 26, 2003 (the “Effective Date”), by and between Epix Medical, Inc., a Delaware corporation having its principal place of business at 00 Xxxxxx Xxxxxx, Xxxxxxxxx, XX 00000-0000 XXX (“EPIX”), and Schering Aktiengesellschaft, a German corporation having its principal place of business at 13342, Berlin, Germany (“SCHERING”). Each of SCHERING, EPIX and their respective Affiliates is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
WHEREAS, EPIX has expertise and proprietary technology related to the discovery, development and commercialization of products for use in magnetic resonance imaging;
WHEREAS, SCHERING has expertise and proprietary technology related to the discovery, development and commercialization of products for use in magnetic resonance imaging;
WHEREAS, XXXX and SCHERING desire to bring their collective expertise, proprietary technology and other resources together in a collaborative effort to discover new technology and products for use in magnetic resonance imaging; and
WHEREAS, EPIX and SCHERING further desire to provide for a series of rights and obligations pertaining to the commercialization of new products arising from their collaborative efforts as set forth herein.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as follows:
1. DEFINITIONS
Whenever used in this Agreement with an initial capital letter, the terms defined in this Section 1 shall have the meanings specified.
1.1 “Affiliate” means any corporation, firm, partnership or other entity which directly or indirectly controls or is controlled by or is under common control with a Party to this Agreement. For purposes of this definition, “control” means ownership, directly or through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity.
1.2 “Audit Disagreement” has the meaning set forth in Section 7.5.3 (b).
1
1.3 “Confidential Information” means (a) all tangible embodiments of Technology produced or discovered by either Party or jointly by the Parties under the Research Program, the prosecution files pertaining to any Joint Patent Rights and all information concerning the terms of this Agreement and (b) with respect to a Party (the “Receiving Party”), all information, Technology and Proprietary Materials which is disclosed by the other Party (the “Disclosing Party”) to the Receiving Party hereunder or to any of its employees, consultants, Affiliates, licensees or Sublicensees, except to the extent that the information described in this Section 1.3(b), (i) as of the date of disclosure is demonstrably known to the Receiving Party or its Affiliates, as shown by written documentation, other than by virtue of a prior confidential disclosure to such Party or its Affiliates; (ii) as of the date of disclosure is in, or subsequently enters, the public domain, through no fault or omission of the Receiving Party; (iii) is obtained from a Third Party having a lawful right to make such disclosure free from any obligation of confidentiality to the Disclosing Party; or (iv) is independently developed by or for the Receiving Party without reference to or reliance upon any Confidential Information of the Disclosing Party as demonstrated by competent written records.
1.4 “Control” or “Controlled” means (a) with respect to Know-How (other than Proprietary Materials) and/or Patent Rights, the possession by a Party of the ability to grant a license or sublicense of such Know-How and/or Patent Rights as provided herein without violating the terms of any agreement or arrangement between such Party and any Third Party and (b) with respect to Proprietary Materials, the possession by a Party of the ability to supply such Proprietary Materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any Third Party.
1.5 “Cost” or “Costs” shall mean expenses incurred by the Parties, determined in a reasonable manner in accordance with GAAP in case of EPIX and IAS in case of SCHERING, and consistent with each Party’s accounting practice.
1.6 “Cost of Goods Sold” shall mean the cost for manufacturing the Licensed Product, using SCHERING’s standard accounting procedures computed in accordance with IAS applied on a consistent basis. Such cost shall include, but not be limited to, the fully burdened cost of all raw materials, auxiliaries and other ingredients, labor and overhead, depreciation, maintenance and repair, destroyed material, production variance, imputed interest on safety stocks and capacity cost for dedicated equipment, for the synthesis, formulation, filling, finishing, labeling, packaging, storing, testing and quality control, and assurance activities, and shall also include reasonable expenses for services and transportation charges and any royalties paid to Third Parties in connection with the manufacturing process or materials used. “Cost of Goods” shall not include general and administrative expenses, sales and marketing costs or costs associated with meeting the chemistry manufacturing and control requirements of the FDA or other regulatory authorities.
1.7 “Designation Notice” has the meaning set forth in Section 2.4.
1.8 “Development Candidates” shall mean Lead Compounds in the Field that progress successfully through the lead optimization process and that are designated according to
2
the criteria in Exhibit 2.4 as “Development Candidates” as well as any modifications thereof during any development process thereafter.
1.9 “Development Costs” shall mean all internal (direct and indirect) and Third Party expenses incurred by EPIX in connection with the Research Program, or by SCHERING following exercise of the SCHERING Option, determined in a reasonable manner in accordance with GAAP. Such expenses include, but are not limited to (i) direct labor (salaries, wages, incentive awards and employee benefits but excluding any employee benefits associated with equity incentive plans); (ii) materials and supplies; (iii) allocated Costs for building space directly dedicated to the development of the Lead Compounds, Development Candidates and/or Licensed Products (including rent, depreciation, amortization and maintenance) but excluding expenses relating to unused capacity, development of other products, and amortization of property, plant and equipment not directly related to development of Lead Compounds, Development Candidates and/or Licensed Products; (iv) Third Party contracts and consulting expenses incurred for services in connection with the development of Lead Compounds, Development Candidates and/or Licensed Products; (v) allocated Costs for information technology directly dedicated to the development of the Lead Compounds, Development Candidates and/or Licensed Products; and (vi) travel and entertainment, telephone, recruiting, training (both internal and external), clinical trial insurance, software, personal computer equipment and support Costs and freight and delivery expenses. Such Costs shall not include General and Administrative Expenses or expenses incurred from departments that are not directly engaged in the development of the Lead Compounds, Development Candidates and/or Licensed Products including, but not limited to, finance and procurement, corporate administration, legal (both external and internal expenses), human resources, business development and licensing, sales and marketing except for Costs of investor relations.
Development activities for which Development Costs are incurred include but are not limited to pre-clinical and clinical work (Phase I-IV trials (such Phase IV trials to be intended to support approval of an NDA, MAA or a supplement or amendment thereto, required as a condition of approval of an NDA, MAA or a supplement or amendment thereto, or required to support continued approval of an NDA, MAA or a supplement or amendment thereto), regulatory filings, Cost of compound for pre-clinical and clinical work (Phase I-IV trials, as described above in this sentence), and all Costs of Lead Compounds, Development Candidates and/or Licensed Products related to regulatory filings in the Territory including CMC Costs.
1.10 “Effective Date” has the meaning set forth in the introductory paragraph.
1.11 “EPIX Background Technology” means collectively all EPIX Patent Rights and EPIX Know-How.
1.12 “EPIX Option” has the meaning set forth in Section 4.2.
1.13 “EPIX Patent Rights” means the Patent Rights, Controlled by EPIX and having claims covering EPIX Know-How, which are already in existence prior to the Effective Date, as identified on Exhibit 1.13 hereto or filed thereafter.
3
1.14 “EPIX Know-How” means all Know-How useful in the Field that is: (a) Controlled by EPIX immediately prior to the Effective Date, or (b) developed or conceived by EPIX on or after the Effective Date in the conduct of activities outside of the Research Program.
1.15 “Field” means the diagnosis or characterization of diseases or conditions in humans through the use of magnetic resonance imaging; provided, however, that the Field shall not include: (i) any products that are subject to a license granted under the Thrombus Development Agreement entered into by and between the Parties as of the Effective Date or the Strategic Collaboration Agreement between EPIX and SCHERING dated June 9, 2000, or (ii) any products already commercialized or in preclinical or clinical development prior to the Effective Date as set forth on Exhibit 1.15 , or (iii) any product, compound or Technology being subject to a contract or collaboration with a Third Party which is already in existence prior to the Effective Date, or any extension or amendment thereof, except for those contracts as to be determined by the RSC.
1.16 “FDA” means the United States Food and Drug Administration or any successor agency.
1.17 “First Commercial Sale” means the date of the first sale of a Licensed Product in the ordinary course of business in any country by a Party or an Affiliate or Sublicensee of such Party after all marketing, pricing and/or reimbursement approvals of the competent health authority(ies) of such country required for sale of such product in such country have been obtained.
1.18 “Full Time Equivalent” or “FTE” means one (1) or more qualified employee(s), contractor(s) or agent(s) of a Party who, collectively, spend time and effort working on a specific project or task equivalent to the time and effort of one (1) full-time employee for one (1) year.
1.19 “General and Administrative Expenses” shall mean all direct and indirect expenses incurred by SCHERING and EPIX in connection with departmental units that are not directly engaged in the research, development, manufacturing, or sales and marketing of Joint Technology, Lead Compounds, Development Candidates and Licensed Products. General and Administrative Expenses shall include, but not be limited to, charges falling within the following, groups: finance, procurement, order entry, corporate administration, legal (both external and internal expenses), human resources, business development and licensing and investor relations. “General and Administrative Expenses” shall exclude the following groups of charges: clinical trial insurance Costs, facilities and information technology. Such expenses shall be determined in accordance with GAAP, consistently applied.
1.20 “IND” means an Investigational New Drug application, as defined in the United States Food, Drug and Cosmetic Act and applicable regulations promulgated thereunder, or the equivalent in any other country.
1.21 “Indemnitee” has the meaning set forth in Section 12.4.
4
1.22 “Indemnitor” has the meaning set forth in Section 12.4.
1.23 “Joint Know-How” means all Know-How that is: (a) developed or conceived by EPIX and/or SCHERING after the Effective Date in the conduct of activities within the Research Program, and/or (b) Controlled jointly by EPIX and SCHERING.
1.24 “Joint Patent Rights” means Patent Rights Controlled by XXXXXXXX and EPIX and having claims covering Joint Know-How, which are filed after the Effective Date.
1.25 “Joint Technology” means collectively all Joint Patent Rights and Joint Know-How.
1.26 “Know-How” means and includes all present and future know-how, inventions, trade secrets, copyrights, data, regulatory submissions and other intellectual property of any kind, whether patentable or not, including Proprietary Materials.
1.27 “Lead Compounds” means compounds that will be the subject of research optimization efforts in the Research Program and that are designated, as provided in Section 2.4, to be “Lead Compounds.”
1.28 “Licensed Product(s)” means any product based upon, derived from or incorporating a Development Candidate or Joint Technology licensed by either SCHERING or EPIX under this Agreement.
1.29 “License Term” has the meaning set forth in Section 7.2.3 of this Agreement.
1.30 “Management Team” means the organizational body for the Research Program as set forth in Section 5.2.
1.31 “MAA” means an application for Regulatory Approval to sell a Product in the European Union.
1.32 “NDA” means a New Drug Application, as defined in the United States Food, Drug and Cosmetic Act and applicable regulations promulgated thereunder.
1.33 “Net Sales” shall meanthe amount invoiced by the selling Party, its Affiliates or sublicensees for sales of a Licensed Product to unaffiliated Third Parties less the following deductions applicable to the Licensed Product for:
(i) transportation charges and insurance charges paid by the selling Party;
(ii) sales and excise taxes or customs duties paid by the selling Party or any other governmental charges imposed upon the sale of the Licensed Product and paid by the selling Party exclusive of taxes on the income of the selling Party;
5
(iii) fees paid to distributors, consignees or agents in connection with the sale of the Licensed Product;
(iv) rebates and premiums granted in connection with the sale of a Licensed Product;
(v) credits to customers on account of governmental requirements, price differences, rejection, outdating, returns or recalls of the Licensed Product;
(vi) quantity discounts, cash discounts or chargebacks granted in connection with the sale of the Licensed Product;
(vii) provisions for price reductions; and
(viii) selling Party’s standard allowance as demonstrated to the other Party’s reasonable satisfaction, and in no case in excess of [*****].
For the purpose of calculating Net Sales, the Parties recognize that (a) the selling Party’s customers may include persons in the chain of commerce who enter into agreements with the selling Party as to price even though title to the Licensed Product does not pass directly from the selling Party to such customers and even though payment for such Licensed Product is not made by such customers directly to the selling Party and (b) in such cases, chargebacks paid by the selling Party to or through a Third Party (such as a wholesaler) can be deducted by the selling Party from gross revenue in order to calculate Net Sales. Any deductions above which involve a payment by the selling Party shall be taken as a deduction against aggregate sales for the period in which the payment or deduction is made.
In the event a Licensed Product is sold in the form of a combination product containing one or more active ingredients in addition to a Licensed Product, Net Sales for such combination product will be adjusted by multiplying actual Net Sales of such combination product by the fraction A / (A+B) where A is the invoice price of the Licensed Product, if sold separately, and B is the invoice price of any other active ingredient or ingredients in the combination, if sold separately. If, on a country-by-country basis, the other active ingredient or ingredients in the combination are not sold separately in that country, Net Sales shall be calculated by multiplying actual Net Sales of such combination product by the fraction A / C where A is the invoice price of the Licensed Product if sold separately, and C is the invoice price of the combination product. If, on a country by country basis, neither the Licensed Product nor the other active component or components of the combination product is sold separately in said country, Net Sales shall be determined between the Parties in good faith.
1.34 “Part or Parts of the Agreement” means either all terms relating to the Research Program or all terms relating to a license granted or optioned under this Agreement, depending on which terms are involved.
6
1.35 “Other Schering Patent(s)” means any patent filed by SCHERING after the Effective Date which incorporates Technology arising out of research activities at SCHERING outside the Field and outside the scope of this Collaboration.
1.36 “Patent Rights” means the rights and interests in and to issued patents and pending patent applications (which for purposes of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention and priority rights) in any country, including all provisional applications, substitutions, continuations, continuations-in-part, divisionals, and renewals, all letters patent granted thereon, and all reissues, reexaminations and extensions thereof, Controlled by a Party.
1.37 “Phase III Clinical Trial” means a pivotal human clinical trial in any country the results of which could be used to establish safety and efficacy of a Product as a basis for a marketing approval application submitted to the FDA, or that would otherwise satisfy requirements of U.S. Statute 21 CFR 312.21(c), or its foreign equivalent.
1.38 “Project Team(s)” means the working group(s) conducting the work in the various research projects under the Research Plan(s) and established in accordance with Section 5.3.
1.39 “Proprietary Materials” means any tangible chemical, biological or physical research materials that are furnished by or on behalf of one Party to the other Party in connection with this Agreement, regardless of whether such materials are specifically designated as proprietary by the transferring Party.
1.40 “[*****]” means the use of [*****] to a [*****] for the purpose of imaging in [*****] or [*****] or for [*****].
1.41 “Regulatory Approval” means any approval, product and establishment license, registration or authorization of any national, federal, state or local regulatory agency, department, bureau or other governmental entity necessary for the manufacture, use, storage, importation, export, transport or sale by a Party of a Licensed Product in a regulatory jurisdiction.
1.42 “Research Plan(s)” means the written plan(s) and description(s) of each research project to be conducted under this Agreement, as to be determined by the RSC.
1.43 “Research Program” means the collaborative research program to be conducted pursuant to this Agreement as reflected in the Research Plan(s), focusing initially in the following three areas; (a) inflammation (including plaque) imaging with magnetic resonance imaging contrast media (including gadofluorines), (b) cardiac perfusion imaging, and (c) high-sensitivity magnetic resonance imaging contrast media.
1.44 “Research Program Term” has the meaning set forth in Section 2.1.
7
1.45 “Research Steering Committee” or “RSC” means the committee of EPIX and SCHERING representatives established pursuant to Section 5.1 hereof to administer the affairs of the Collaboration.
1.46 “SCHERING Background Technology” means collectively all SCHERING Patent Rights and SCHERING Know-How.
1.47 “SCHERING Know-How” means all Know-How useful in the Field that is: (a) Controlled by SCHERING immediately prior to the Effective Date, or (b) developed or conceived by SCHERING on or after the Effective Date in the conduct of activities outside of the Research Program.
1.48 “SCHERING Option” has the meaning set forth in Section 4.1.
1.49 “SCHERING Patent Rights” means the Patent Rights, Controlled by XXXXXXXX and having claims covering SCHERING Know-How, which are already in existence prior to the Effective Date, as identified on Exhibit 1.49 hereto or filed thereafter.
1.50 “Sublicense Income” means all payments received by a Party from a sublicensee in connection with the grant of a sublicense under a development and a commercial license in accordance with Section 4.4 or Section 7.2, including without limitation, royalties, up-fronts, technology access fees, milestones and fifty percent (50%) of the premium over fair market value paid to such Party in connection with the issuance of securities of such Party where fair market value is based on the number of securities issued multiplied by the average closing price of the stock as quoted on the stock exchange (NASDAQ or Deutsche Boerse XETRA, respectively), such average based on a twenty (20) business day period, but excluding (a) payments made to support or fund research and development activities and (c) payments made for other rights or tangible property to the extent not in excess of the fair market value of such other rights or tangible property.
1.51 “Term” has the meaning set forth in Section 8.1.
1.52 “Territory” means all countries of the world.
1.53 “Third Party” means any person or entity other than SCHERING and EPIX and their respective Affiliates.
2.1 Objectives of the Research Program; Term; Exclusivity. The objectives of the Research Program shall be the discovery and optimization of compounds that may become Licensed Products and Joint Technology that is useful in the Field. The Research Program shall commence on the Effective Date and shall continue for a period of three (3) years, with an option to extend the Program for two (2) additional years upon mutual agreement of both Parties no
8
later than ninety (90) days prior to the expiration of the initial term (the “Research Program Term”). Neither Party shall perform any research, in the Field during the Research Program Term outside of this collaboration.
2.2 Obligations of the Parties.
2.2.1 Research Plan(s). The work under the Research Program will be organized into various research projects to be conducted in accordance with a Research Plan, which may be amended from time-to-time during the Research Program Term. The initial Research Plan will be determined at the first meeting of the RSC. The Parties will execute each Research Plan in accordance with the requirements set forth herein (for example, with the diligence specified in Section 2.2.2). For each of the research projects one of the Parties shall be designated by the Management Team as being primarily responsible for the various tasks under the relevant Research Plan. Each Research Plan may be modified upon proposal for such modification by the Project Team to the Management Team, which shall discuss and decide about such modifications.
2.2.2 Due Diligence; Commitment of FTE’s. Each Party will use commercially reasonable efforts to perform all aspects of its obligations under the relevant Research Plan(s) consistent with the efforts it devotes to its other collaborations with commercial entities, and in accordance with all applicable laws, ordinances, rules, regulations, orders, licenses and other requirements now or hereafter in effect. Each Party shall devote [*****] FTE’s exclusively to the performance of its obligations under the Research Program. The Management Team shall allocate the actual number of FTE’s for each research project. [*****] [*****] months after the Effective Date EPIX may start to reduce its number of FTE’s to a [*****]. After such reduction of FTE’s [*****] the [*****]. The individuals whom each Party commits to the performance of the Research Program shall have the training and experience required to perform the tasks assigned to him or her by each Party in a manner consistent with this standards set forth in this Section 2.2.2. Each Party will maintain a list of the individuals it commits to the performance of the Research Program and shall share such list with the other Party solely to facilitate the performance of the Research Program and to allow each Party to monitor the other Party’s compliance with this Section. The list of individuals each Party shall commit to the performance of the Research Program shall be determined and exchanged at the first meeting of the RSC.
2.2.3 Information Exchange; Reports. The Party responsible for a research project shall keep the Management Team fully informed about the status of the Research Plan for which it is responsible. In addition, each Project Team shall submit a written report, describing the progress of the work done by it under the relevant Research Plan in reasonable detail, to the Research Steering Committee (RSC) at least seven (7) days prior to each meeting of the RSC. The Parties expect that the exchange of information and materials may involve on-site visits and longer exchange visits by scientists of one Party to the facilities of the other Party. Such visits will have defined purposes, include a reasonable number of participants and be scheduled reasonably in advance.
9
2.2.4 Supply of Proprietary Materials. From time-to-time during the Term of this Agreement, a Party (the “Transferor”) may supply the other Party (the “Recipient”) with its Proprietary Materials for use in the Research Program or for any additional development activities agreed upon by the Parties. In connection therewith, the Recipient hereby agrees that: (a) it shall not use Proprietary Materials for any purpose other than exercising any rights granted to it or reserved by it hereunder, (b) it shall use the Proprietary Materials only in compliance with all applicable, federal, state, and local laws and regulations, (c) it shall not transfer any Proprietary Materials to any Third Party without the prior written consent of the Transferor, except as expressly permitted hereby, (d) the Transferor shall retain full ownership of all such Proprietary Materials and (e) upon the expiration or termination of this Agreement, the Recipient shall at the instruction of the Transferor either destroy or return any Proprietary Materials which are not the subject of the grant of a continuing license hereunder.
2.3 Contract Services and Goods. The Research Program indicates the Parties’ currently anticipated needs for contracted services and goods. The decision on contracting any goods and services from Third Parties shall be made by the Management Team. SCHERING shall be responsible for funding such contracted services and goods if needed and as indicated in one of the Research Plan(s) on a case-by-case basis up to a maximum of $[*****] for each full calendar year, such amount to be reduced ratably for any partial year. The cost of any other contracted goods and services as are provided for in the Research Plan(s) shall be shared equally by the Parties. As is set forth in more detail in Section 2.2.2, the Parties shall commit [*****] FTE’s each to the performance of the Research Program. In the event EPIX in fact commits less than [*****] FTE’s to the performance of the Research Program, then the funding for contracted goods and services set forth herein shall be reduced ratably over such period of time unless the RSC shall determine otherwise. With regard to all contracts already executed prior to the Effective Date for which the Parties may agree to include them in the Field and, therefore, this Agreement, all payments due under those contracts for the calendar year 2003 shall be paid pro rata under this Section 2.3 as of the Effective Date. It is understood between the Parties that the inclusion of any such Third Party contract may only be included in this Agreement upon the Third Party’s consent. [*****] the Parties agree [*****] of [*****] does [*****], Epix and Schering [*****] of [*****] contract as [*****] or [*****]
2.4 Discovery of Lead Compounds. The initial work under the Research Program will be focused on the discovery of compounds meeting criteria set forth in Exhibit 2.4A. Upon proposal of the relevant Project Team the Management Team shall submit the most promising compounds to the RSC for designation as “Lead Compounds” in accordance with the criteria set forth in Exhibit 2.4 A. Lead Compounds will undergo additional lead optimization efforts in order to meet the criteria identified on Exhibit 2.4 B. Upon proposal of the relevant Project Team, the Management Team shall decide upon submission of a Lead Compound to the RSC for designation as a Development Candidate. If it has been submitted by the Management Team and the RSC has positively decided to designate the Lead Compound as a Development Candidate, the RSC shall provide written notice to SCHERING and EPIX with its decision (the “Designation Notice”). It is understood that the SCHERING members on the RSC have the authority to render any decision hereunder only after an internal review and approval process for
10
any Lead Compound or Development Candidate at SCHERING. Such review process shall be initiated by a SCHERING RSC or Management Team member as soon as possible and shall in any case be finished within ninety (90) days after submission of a Lead Compound or Development Candidate to the RSC by the Management Team.
3.1 Payments by SCHERING. In consideration of the performance by EPIX of the Research Program, SCHERING shall make payments to EPIX in the aggregate amount of $[*****] (= $[*****] per FTE) for each twelve (12) month period during the Research Program Term. Such annual payment shall be made in equal quarterly installments with the first such payment being due and payable within ten (10) business days of the Effective Date and with subsequent payments becoming due and payable every three (3) months thereafter during the Research Program Term. The annual payment shall be reduced accordingly if and whenever EPIX reduces its committed FTEs in accordance with Section 2.2.2.
3.2 Loan by SCHERING to EPIX. SCHERING shall provide a loan of up to $15,000,000 to EPIX in accordance with the terms and conditions set forth in the Loan Agreement and the Security Agreement, copies of which are attached hereto as Exhibit 3.2A and Exhibit 3.2B respectively.
4. OPTION RIGHTS FOR DEVELOPMENT CANDIDATES AND JOINT TECHNOLOGY
4.1 SCHERING License Option.
4.1.1 Option Grant. EPIX hereby grants to SCHERING the exclusive right and option (the “SCHERING Option”) to obtain an exclusive license under the terms set forth in Section 7 to develop and commercialize products based upon, derived from or incorporating a Development Candidate with the right to sublicense (the “SCHERING Option”).
4.1.2 Exercise of SCHERING Option. Upon the delivery by the RSC to SCHERING and EPIX of a Designation Notice, SCHERING will have a period of [*****] [*****] to determine whether to exercise the SCHERING Option with respect to the Development Candidate identified in such notice. SCHERING shall notify EPIX of its decision within such [*****] period. If no notice is provided to EPIX within such [*****] period, the SCHERING Option for such Development Candidate shall expire.
4.2 Failure to Exercise; EPIX License Option. For all Development Candidates for which SCHERING fails to exercise the SCHERING Option, SCHERING hereby grants to EPIX the exclusive right and option (the “EPIX Option”) to obtain an exclusive license under the terms set forth in Section 7 and to further develop and commercialize products based upon, derived from or incorporating such Development Candidate, with the right to sublicense. Each EPIX
11
Option shall commence upon the expiration of the corresponding SCHERING Option and shall be exercised within [*****] upon notification to SCHERING. If no notice is provided by EPIX within such [*****] period, the EPIX Option for such Development Candidate shall expire.
4.3 Failure to Exercise the Option by both Parties. In case that neither SCHERING nor EPIX exercise their respective option for the relevant Development Candidate during the period set forth in Section 4.1 or Section 4.2 as applicable, both the EPIX Option and the SCHERING Option shall again become operative and either Party may thereafter exercise its option by written notice to the other Party. Options shall then be exercisable on a first-come, first-served basis.
4.4 Joint Technology Option. Each Party hereby grants to the other the right and option to obtain an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, under such Party’s interest in the Joint Technology, to the extent required to permit such other Party to develop, make, have made, use, sell, promote, have sold, and import a product based upon, derived from or incorporating Joint Technology for use in [*****] the [*****]. The Joint Technology option shall not apply to Development Candidates. This option shall commence upon the expiration of the Research Program and shall continue in full force and effect until the [*****] anniversary of the termination of the Research Program. The Joint Technology option shall be exercisable by written notice from one Party to the other Party and on a first-come, first-served basis. For all exclusive licenses optioned under this Section 4.4 the royalty rate of Section 7.2.1 (b) (royalties for [*****] shall apply as well as Section 7.2.3 and Section 7.5. Notwithstanding any rights which the Parties may have at law or otherwise as joint owners of the Joint Technology, the Parties hereby agree that neither of them will practice any Joint Technology, except as provided in this Section 4.4 or in their performance hereunder, without the express written consent of the other Party during the Term and for a period of [*****] years thereafter.
5. ADMINISTRATION OF THE COLLABORATION
5.1 Establishment and Function of RSC. EPIX and SCHERING hereby establish a “Research Steering Committee” (or “RSC”) to oversee the Research Program. The RSC shall have the responsibilities as set forth in Section 5.1.4.
5.1.1 Membership.
(a) The RSC shall be comprised of two (2) named representatives of SCHERING and two (2) named representatives of EPIX. The RSC representatives shall be appointed as soon as possible after the Effective Date and shall meet as needed but not less than twice annually. Such meetings shall be at times and places or in such form as the members of the RSC shall agree, and may take place by conference call or videoconference. Each Party shall have the right to have other employees of the same Party (or consultants to such Party, with the advance permission of the other Party) present at and participating in any RSC meeting provided that the names, titles, and subject matter to be addressed by such additional attendees are
12
submitted in writing to the other Party at least three (3) business days in advance of the meeting, and that neither Party has more than five (5) attendees at a meeting without the advance permission of the other Party.
(b) A Party may change its representative to the RSC at any time. Members of the RSC may be represented at any meeting by an authorized designee. In making any approval, determination or taking any other action delegated to the RSC, SCHERING and EPIX shall each have one vote on the RSC, regardless of how many representatives each Party may have in attendance at any RSC meeting.
5.1.2 Chair. The RSC shall initially be chaired by the EPIX representative (the “Chair”) and thereafter the Chair shall alternate from meeting to meeting between the representative of SCHERING and the representative of EPIX.
5.1.3 Minutes. The RSC shall keep accurate minutes of its deliberations, which record all proposed decisions and all material actions recommended or taken. The Chair shall be responsible for the preparation of draft minutes. Draft minutes shall be sent to the other member of the RSC within ten (10) working days after each meeting. The draft minutes shall be edited by the Chair based on comments from the other member of the RSC to be provided within ten (10) working days and shall be distributed to the other member by the Chair within thirty (30) working days after the meeting, and in any case no later than one (1) week prior to the next meeting. All minutes of the RSC shall at all times be available to both Parties.
5.1.4 Responsibilities of the RSC. The RSC shall be responsible for making strategic decisions relating to the overall Research Program, including without limitation, the following matters:
(a) determination of a Research Plan and any amendments thereto or changes thereof;
(b) monitoring the progress of the Research Program based upon information from the Management Team;
(c) approving resource allocation and approving priorities within the Research Program with regard to each Research Plan;
(d) determination of potential Lead Compounds;
(e) determination of potential Development Candidates; and
(f) dispute resolution for disputes among Management Team.
5.1.5 RSC Dispute Resolution. In the event that the RSC shall not be able to reach a decision or take an action on any matter that is reserved to the RSC hereunder, then such RSC decisions shall first be referred for resolution to the Chief Executive Officer of EPIX and the Head of Corporate Research of SCHERING for attempted resolution by good faith negotiation. Such good faith negotiation may include the appointment by either Party of an
13
unaffiliated expert chosen on the basis of such person’s experience and expertise in the particular type of issue that is unresolved, in order to advise such officers on the matter. If such officers are unable to resolve the matter within ninety (90) days, then SCHERING shall have authority to make the decision.
5.2 Establishment and Function of Management Team. XXXX and SCHERING hereby establish a “Management Team” to plan and administer the execution of the various projects composing the Research Program and reflected by the Research Plan(s). The Management Team shall have the responsibilities as set forth in Section 5.2.4.
5.2.1 Membership.
(a) The Management Team shall be comprised of two (2) named representatives of SCHERING and two (2) named representatives of EPIX. Each such representative shall be appointed as soon as possible after the Effective Date and shall meet as needed but not less than four times annually. Such meetings shall be at times and places or in such form as the members of the Management Team shall agree, and may take place by conference call or videoconference. Each Party shall have the right to have other employees of the same Party (or consultants to such Party, with the advance permission of the other Party) present at and participating in any Management Team meeting provided that the names, titles, and subject matter to be addressed by such additional attendees are submitted in writing to the other Party at least three (3) business days in advance of the meeting, and that neither Party has more than three (3) attendees at a meeting without the advance permission of the other Party.
(b) A Party may change its representatives to the Management Team at any time. Members of the Management Team may be represented at any meeting by an authorized designee. In making any approval, determination or taking any other action delegated to the Management Team, SCHERING and EPIX shall each have one vote on the Management Team, regardless of how many representatives each Party may have in attendance at any Management Team meeting.
5.2.2 Chair. The Team shall initially be chaired by one of the EPIX representatives (the “Chair”) and thereafter the Chair shall alternate from meeting to meeting between one of the representatives of SCHERING and one of the representatives of EPIX.
5.2.3 Minutes. The Management Team shall keep accurate minutes of its deliberations, which record all proposed decisions and all actions recommended or taken. The Chair shall be responsible for the preparation of draft minutes. Draft minutes shall be sent to the other member of the Management Team within ten (10) working days after each meeting. The draft minutes shall be edited by the Chair based on comments from the other member of the Management Team to be provided within ten (10) working days and shall be distributed to the other member by the Chair within thirty (30) days after the meeting, but in no case later than one (1) week prior to the next meeting of the Management Team. All records of the Management Team shall at all times be available to both Parties.
14
5.2.4 Responsibilities of Management Team. The Management Team shall be responsible for making decisions that are relevant to the individual research projects within the Research Program, including without limitation, the following matters:
(a) allocating FTE’s and resources to the research projects (to be approved by RSC)
(b) choosing project management tools;
(c) monitoring the progress of each research project and providing information to the RSC
(d) selection of contract service providers
(e) proposing potential Lead Compounds to RSC;
(f) proposing potential Development Candidates to RSC.
5.2.5 Management Team Dispute Resolution. In the event that the Management Team shall not be able to reach a decision or take an action on any matter that is reserved to the Management Team hereunder, then such dispute shall first be referred for resolution to the RSC. If the RSC can not agree on the solution for the dispute, Section 5.1.5 shall apply accordingly.
5.3 Establishment of Project Team(s). Upon consultation with the Party primarily responsible for the relevant research project, the Management Team shall determine and nominate a Project Team consisting of all FTE’s working on that research project.
6. DEVELOPMENT AND COMMERCIALIZATION OF DEVELOPMENT CANDIDATES
6.1 Development and Commercialization Obligations.
6.1.1 SCHERING’s obligations. SCHERING shall use diligent efforts to undertake the development and commercialization of each Licensed Product licensed hereunder in the Field, using the level of resources and effort which are consistent with those which it would apply to a product of comparable potential resulting from its own research programs.
6.1.2 EPIX’ obligations. EPIX shall use diligent efforts to undertake the development and commercialization of each Licensed Product licensed hereunder in the Field, using the level of resources and effort which are consistent with those which it would apply to a product of comparable potential resulting from its own research programs.
6.2 Progress Reports. The developing Party shall keep the other Party regularly informed on all development activities for a Licensed Product, at least by annual up-date reports.
15
6.3 Clinical Development by EPIX. In the event that SCHERING desires for EPIX to perform additional development work on a licensed Development Candidate, including without limitation, clinical trials, then EPIX and SCHERING shall agree on a development plan to advance such Development Candidate through to completion of a proof-of-concept clinical trial. Such development plan will include a protocol for such proof-of-concept clinical trial and estimated Development Cost for such proof-of-concept clinical trial. SCHERING shall deliver the development plan to EPIX upon its completion. EPIX will then have a period of thirty (30) days to determine, in its sole discretion, whether to accept the obligation to undertake the additional work described in the development plan. In the event that XXXX agrees to perform such work, EPIX will so notify SCHERING in writing and EPIX will perform the work, in accordance with the diligence standards provided hereunder. Such additional work shall not be deemed to be part of the Research Program and EPIX shall not be permitted to count the efforts it makes under such development plan as work performed under the Research Program for purposes of determining whether it has met the requirement that it commit [*****] to the work under the Research Program. SCHERING shall reimburse, on a monthly basis, one hundred percent (100%) of all Development Costs incurred by EPIX in performing such development work. EPIX shall invoice SCHERING for such amounts at the end of each calendar month and shall provide sufficient detail of the costs and expenses incurred.
6.4 Record Keeping. EPIX and SCHERING shall each maintain records in sufficient detail and in accordance with commonly accepted industry standards which will document in a manner appropriate for purposes of supporting the filing of potential patent applications, all work done and results achieved in the performance of the Research Program (including all data in the form required under any applicable governmental regulations). Subject to Article 10 hereof, EPIX and SCHERING shall each provide the other the right to inspect and copy such records to the extent reasonably required for the performance of its obligations under this Agreement and shall not use such records or information except to the extent otherwise permitted by this Agreement.
7.1 Research Licenses.
7.1.1 License to SCHERING. EPIX hereby grants to SCHERING and its Affiliates a fully paid-up, non-exclusive, royalty-free, worldwide license in the Field, without the right to grant sublicenses, under EPIX Background Technology, for the sole purpose of conducting the activities required in the performance of its obligations hereunder as part of the Research Program, during the Research Program Term.
7.1.2 License to EPIX. SCHERING hereby grants to EPIX and its Affiliates a paid-up, non-exclusive, royalty-free, worldwide license in the Field, without the right to grant sublicenses under SCHERING Background Technology for the sole purpose of conducting the activities required in the performance of its obligations hereunder as part of the Research Program, during the Research Program Term.
16
7.2 Development and Commercialization Licenses.
7.2.1 Licenses to SCHERING
(a) Subject to SCHERING’s exercise of the SCHERING Option, EPIX hereby grants to SCHERING an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under the EPIX Background Technology and EPIX’ interest in the Joint Technology to the extent required to permit SCHERING to develop, make, have made, use, promote, sell, have sold and import Licensed Products, for use in the Field, in the Territory during the License Term.
(b) EPIX hereby grants to SCHERING an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under EPIX’ interest in the Joint Technology to permit SCHERING to develop, make, have made, use, promote, sell, have sold and import products for use in the [*****] during the License Term. Anything to the contrary herein notwithstanding, products which are developed, made, used, promoted, sold or imported under this license shall be “Licensed Products” for all purposes under this Agreement except that the following Sections shall not apply to such products: Section 6.1.1, 6.2, 7.2.3(b) and Section 7.4. SCHERING shall pay a royalty on products under this Section equal to [*****] [*****] of Net Sales. SCHERING shall inform EPIX about the First Commercial Sale of any product under this license. For the sake of clarity the Parties agree that any royalty obligation under this Section expires upon the expiration of the last to expire of the relevant Patent Rights in the country covering the product.
7.2.2 Licenses to EPIX
(a) Subject to EPIX’s exercise of the EPIX Option, SCHERING hereby grants to EPIX an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under the SCHERING Background Technology and SCHERING’s interest in the Joint Technology to the extent required to permit EPIX to develop, make, have made, use, sell, promote, have sold and import Licensed Products, for use in the Field, in the Territory during the License Term.
(b) SCHERING hereby grants to EPIX a non-exclusive, worldwide, royalty-free license, without the right to grant sublicenses under Other Schering Patent(s) to the extent necessary to permit EPIX to develop, make, have made, use, promote, sell, have sold and import Licensed Products in the Field.
7.2.3 License Term. The term of any license granted pursuant to Section 7.2 or Section 4.4 with respect to any Licensed Product, shall commence (i) in case of a license granted under Section 7.2.1 (a) or 7.2.2 (a) upon the date the option giving rise to such license is exercised in accordance with this Agreement, or (ii) in case of a license granted under Section 7.2.1 (b), 7.2.2 (b) or 4.4 upon the existence of the relevant Joint Technology, or Other Schering Patent(s) and shall continue on a country-by-country and product-by-product basis until the longer of: (a) the expiration of the last to expire of the relevant Patent Rights in the country
17
covering the Licensed Product and (b) the expiration of [*****] from the First Commercial Sale in such country of such Licensed Product (the “License Term”). Upon the expiration of the License Term for each Licensed Product, such license shall convert automatically to a paid up, royalty-free license to develop, manufacture, use, sale or import such Licensed Product. The Parties hereby acknowledge that during the License Term royalties may be payable hereunder for a Licensed Product that is not covered by any claim in Patent Rights subject to a license granted hereunder. Under such circumstances, royalties shall be payable as set forth herein, but at a reduced rate equal to fifty percent (50 %) of the royalty rate which would otherwise be payable hereunder, if the manufacture, use, sale or importation of such Licensed Product were covered by a claim in Patent Rights subject to a license granted hereunder. Such reduced royalties shall be in consideration of: (i) the commercial advantage and background information gained from the Research Program, (ii) the contribution of the unpatented Technology to the successful development of the Licensed Product and (iii) the exclusivity of the Collaboration.
7.3 Payments of EPIX
7.3.1 Milestones. EPIX shall make the following one-time milestone payments to SCHERING for each EPIX Licensed Product. Such payments shall be due and payable within thirty (30) days following the achievement of the corresponding milestone event.
|
Milestone Event |
|
Milestone
Payment |
|
|
|
|
|
|
|
|
|
[*****] |
|
$ |
[*****] |
|
|
[*****] |
|
$ |
[*****] |
|
|
[*****] |
|
$ |
[*****] |
|
|
[*****] |
|
$ |
[*****] |
|
7.3.2 Royalties by EPIX.
(a) EPIX shall pay SCHERING a royalty based on total annual Net Sales of each Licensed Product sold by EPIX and/or its Affiliates during the License Term, at the following rates:
|
On Annual Net Sales of a |
|
Royalty Rate (%) |
|
|
|
|
|
|
|
Above $ [*****]$ [*****] |
|
[*****] |
% |
|
|
|
|
|
|
Above $ [*****] |
|
[*****] |
% |
(b) EPIX shall pay SCHERING [*****] of any and all Sublicense Income within thirty (30) days of receipt by EPIX.
18
7.4 Royalties by SCHERING; Buy-up Option EPIX.
7.4.1 Royalty Rates. SCHERING shall pay EPIX a royalty based on total annual Net Sales of each Licensed Product sold by SCHERING and/or its Affiliates during the License Term at the following rates:
|
On Annual Net Sales of a |
|
Royalty Rate (%) |
|
|
|
|
|
|
|
Above $[*****] and up to $[*****] |
|
[*****] |
% |
|
|
|
|
|
|
Above $[*****] |
|
[*****] |
% |
7.4.2 Buy-up Option EPIX. Notwithstanding the foregoing, EPIX shall have the option of increasing the above royalty rates payable with respect to each Licensed Product sold by SCHERING by reimbursing SCHERING for a percentage of all the Development Costs for such Licensed Product incurred by SCHERING as follows. For every [*****] of the total Development Costs incurred by SCHERING after the date SCHERING exercises the SCHERING Option for a particular Licensed Product that EPIX reimburses SCHERING for, the royalty rate otherwise payable under the table above will be increased by [*****] [*****]. This option is limited such that EPIX cannot reimburse SCHERING for more than [*****] of such Development Costs for any Licensed Product and so the maximum royalty rates payable for any SCHERING Licensed Product are [*****] and [*****]; provided, however, if the [*****] for any Licensed Product is [*****] than [*****] of the [*****] of [*****], then [*****] this [*****] hereunder. EPIX must exercise this option with respect to a Licensed Product by providing written notice to SCHERING within [*****] months after the day on which SCHERING exercises the SCHERING Option relating to such Licensed Product. If EPIX fails to provide notice within such [*****] month period, this option shall expire with respect to such Licensed Product and shall be of no further force or effect.
7.4.3 Payments of EPIX under Buy-up Option. Within one (1) month from the end of the calendar quarter in which EPIX has exercised its buy-up option and on a quarterly basis thereafter, EPIX shall pay its share of the Development Costs incurred by SCHERING during the relevant calendar quarter, except that the first such payment shall include reimbursement based on total Development Costs incurred by SCHERING from the date it exercised the SCHERING Option. The Development Costs incurred by SCHERING during each calendar quarter shall be converted from EURO into United States Dollars by the EURO Foreign Exchange Reference Rate published by the European Central Bank in Frankfurt/Main on the last day of the applicable calendar quarter. The corresponding calculation will be provided by SCHERING to EPIX within fifteen (15) business days from the end of the respective calendar quarter.
7.4.4 Sublicense Income. SCHERING shall pay EPIX [*****] of any and all
19
Sublicense Income within thirty (30) days of receipt by SCHERING.
7.5 General License Conditions.
7.5.1 Payment Dates and Reports. All royalty payments on Net Sales shall be paid within sixty (60) days after the end of each calendar quarter in which such Net Sales are made. Such payments shall be accompanied by a report for the applicable calendar quarter showing the Net Sales of each Licensed Product sold, the applicable royalty rate for such Licensed Product, and a calculation of the amount of royalty due.
7.5.2 Payments; Currency Conversion.
(a) Payments. Payments by either Party to the other Party under this Agreement shall be made in United States dollars by wire transfer of immediately available funds to an account at a commercial bank designated by the receiving Party at least ten (10) Business Days before such payment is due.
(b) Royalty Payments within SCHERING. The calculation of royalty payments within SCHERING is based on Euro. Therefore, where payments are based on Net Sales in countries other than the member states of the European Monetary Union, the amount of such Net Sales expressed in the currency of each country shall be converted into Euro at the Euro Foreign Exchange Reference Rates published by the European Central Bank in Frankfurt / Main, Germany on the last Business Day of the applicable calendar quarter. The resulting Euro amount will be converted into United States dollars again at the Euro Foreign Exchange Reference Rates published by the European Central Bank in Frankfurt / Main, Germany on the last Business Day of the applicable calendar quarter. These Euro Foreign Exchange Reference Rates are, as of the effective date, published on Reuters screen <ECB37>. If no Euro Foreign Exchange Reference Rate is determined for the relevant currency the parties shall agree upon another reference rate.
(c) Royalty Payments within EPIX. The calculation of royalty payments within EPIX is based on United States dollars. Therefore, where payments are based on Net Sales in countries other than the United States, the amount of such Net Sales expressed in the currency of each country shall be converted into United States dollars at the Euro Foreign Exchange Reference Rates published by the European Central Bank in Frankfurt / Main, Germany on the last Business Day of the applicable calendar quarter. If no Euro Foreign Exchange Reference Rate is determined for the relevant currency the parties shall agree upon another reference rate.
7.5.3 Records; Audit Rights; Disputes.
(a) Records of Revenues and Expenses; Audit Rights. Each Party will maintain complete and accurate records which are relevant to the determination of Development Costs, and royalty payments under this Agreement and such records shall be open during reasonable business hours for a period of two (2) years from creation of individual records for examination at the other Party’s expense and not more often than once each calendar year by a
20
certified public accountant selected by the other Party (subject to the consent of the Party to be audited, such consent not to be unreasonably withheld or delayed), or the other Party’s internal accountants (unless the Party to be audited objects to the use of such internal accountants) for the sole purpose of verifying for the inspecting Party the correctness of calculations and classifications of such Development Costs and royalty payments under this Agreement. Each Party shall bear its own Costs related to such audit; provided, that, for any underpayments greater than [*****] of annual Development Costs and/or royalty payments (as the case may be) by the audited Party, the audited Party shall pay the other Party the amount of underpayment, together with interest as provided herein, from the time the amount was due and the inspecting Party’s out-of-pocket expenses related to the audit. For any underpayments less than [*****] of annual Development Costs and/or royalty payments (as the case may be), found under this Section, the audited Party shall pay the inspecting Party the amount of the underpayment. Any overpayments by the audited Party will be refunded to the audited Party or credited to future payments by the audited Party to the inspecting Party, at the audited Party’s election.
(b) Resolution of Payment Disputes. Except as set forth in this Section, the provisions of Section 13.6 shall not be applicable to disputes described in this Section. If there is a dispute between the Parties following any audit performed pursuant to this Section (an “Audit Disagreement”): (i) within thirty (30) business days of the identification of the Audit Disagreement and notice thereof to the other Party, the Parties shall jointly select a recognized international accounting firm to act as an independent expert to resolve such Audit Disagreement; (ii) the Audit Disagreement submitted for resolution shall be described by the Parties to the independent expert, which description may be in written or oral form, within ten (10) business days of the selection of such independent expert; (iii) the independent expert shall render a decision on the matter as soon as practicable; (iv) the decision of the independent expert shall be final and binding unless such Audit Disagreement involves alleged fraud, breach of this Agreement or construction or interpretation of any of the terms and conditions thereof, which Audit Disagreements shall be resolved as set forth in Section 13.6; and (v) all fees and expenses of the independent expert, including any Third Party support staff or other costs incurred with respect to carrying out the procedures specified at the direction of the independent expert in connection with such Audit Disagreement, shall be borne by each Party in inverse proportion to the disputed amounts awarded to such Party by the independent expert through such decision (e.g., EPIX disputes $100; the independent expert awards EPIX $60; EPIX pays for forty percent (40%) of the independent expert’s costs, and SCHERING pays for sixty percent (60%) of the independent expert’s costs.)
(c) Payments; Interest. Any payments due under this Agreement shall be due on such date as specified in the Agreement and, in the event such date is not a business day, then the next succeeding business day. Any failure by a Party to make a payment within ten (10) days after the date when due shall obligate such Party to pay computed interest, the interest period commencing on the due date and ending on the payment day, to the receiving Party at a rate per annum equal [*****]. The interest shall be computed on the basis of a 365/360 year; interest shall be compounded annually in arrears. Such interest shall be due and payable on the tender of the underlying principle payment.
21
(d) Financial Procedures. Each Party shall include in any agreement with its Affiliates or sublicensees terms requiring such party to retain records as required in this Section 7.5.3 and to permit the such Party to inspect such records as required by this Section 7.5.3.
7.5.4 Taxes. Each Party shall pay any and all taxes levied on account of signing fees, research and development funding, milestone payments, royalties or other payments received from the other Party under this Agreement. If laws or regulations require that taxes be withheld by the paying Party on any such payments, the paying Party shall: (i) deduct those taxes from the remittable payment; (ii) timely pay the deducted taxes to the proper taxing authority; and (iii) send proof of payment to the receiving Party within thirty (30) days of receipt of confirmation of payment from the relevant taxing authority.
7.5.5 Retained Rights. Each Party reserves the right to practice all Know-How and Patent Rights that it may Control to the extent not expressly subject to a right, license or option hereunder. No rights are granted hereunder by implication or estoppel.
8. TERMINATION
8.1 Term. The term of this Agreement shall commence on the Effective Date and shall continue until the last to occur of the following: (i) the tenth (10th) anniversary of the expiration or termination of the Research Program Term and (ii) the expiration or termination of the License Term for the last Licensed Product (the “Term”).
8.2 Termination By Either Party. This Agreement may be terminated partially or in its entirety at any time by either Party as follows:
8.2.1 Termination for Breach. If either Party commits a material breach of this Agreement, the other Party may notify the breaching Party in writing of such breach, setting forth the nature of the breach in reasonable detail. If the breaching Party fails to cure such breach within thirty (30) days (in the case of a payment due under this Agreement) or sixty (60) days (in the case of any other breach) of the receipt of the foregoing notice from the non-breaching Party, then, subject to the terms of this Section 8.2.1, the non-breaching Party may terminate (i) the respective Part of this Agreement which is impacted by the uncured material breach, or (ii) if the breach is of a general nature having a material impact on all Parts, the entire Agreement effective immediately upon a second written notice to the breaching Party. The right of either Party to terminate this Agreement as herein above provided shall not be affected in any way by its waiver of, or failure to take action with respect to any previous default.
8.2.2 Termination for Insolvency. In the event that either Party files for protection under bankruptcy laws, makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which is not discharged within sixty (60) days of the filing thereof, then the other Party may terminate this Agreement effective immediately upon written notice to such Party.
22
8.2.3 Termination for Convenience. Either Party may terminate the Research Program upon six (6) months prior written notice to the other Party. Either Party may terminate any license granted to it hereunder upon written notice to the other Party. Neither Party may, under this Section 8.2.3, terminate a license or option granted to the other Party under this Agreement.
8.3 Consequences of Termination. In the event of a termination of this Agreement in part or in its entirety pursuant to Section 8.2 above, all Proprietary Materials shall be returned by each Party to the Party which Controls such Proprietary Materials to the extent required by the fact of a partial or total termination of this Agreement.
8.4 Surviving Provisions. Termination and expiration of this Agreement for any reason shall be without prejudice to:
(a) the rights and obligations of the Parties herein which survive such expiration or termination by their terms, including without limitation, those provided in Sections 2.2.4, 4.4, 6.4, 7.3, 7.4, 7.5, 8.3, 8.4, 9.3.2, 13.4, 13.5, 13.6 and Articles 9, 10, 11 and 12, all of which shall survive such expiration or termination; and
(b) any other rights or remedies provided at law or equity which either Party may otherwise have against the other.
9. INTELLECTUAL PROPERTY RIGHTS
9.1 Disclosure of Inventions. Each Party shall promptly inform the other about all Know-How that is conceived, made or developed in the course of carrying out the Research Program by employees or agents of either of them or their Affiliates, alone or jointly with employees or consultants of the other Party or its Affiliates.
9.2 Ownership.
9.2.1 EPIX Background Technology. As between the Parties, EPIX shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to any and all EPIX Background Technology with full rights to license or sublicense, subject to the obligations to SCHERING as set forth herein.
9.2.2 SCHERING Background Technology. As between the Parties, SCHERING shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to any and all SCHERING Background Technology, with full rights to license or sublicense, subject to the obligations to EPIX as set forth herein.
9.2.3 Joint Technology . SCHERING and EPIX shall jointly own all Joint Technology, subject to the rights of, and the licenses granted to, each Party hereunder.
9.3 Patent Coordinators. EPIX and SCHERING shall each appoint a Patent Coordinator, reasonably acceptable to the other Party, who shall serve as such Party’s primary
23
liaison with the other Party on matters relating to patent filing, prosecution, maintenance and enforcement. Each Party may replace its Patent Coordinator at any time by notice in writing to the other Party. The initial Patent Coordinators shall be:
For EPIX: Xx. Xxxx XxXxxx
For SCHERING: Xx. Xxxxxxx Xxxxxxx
The Patent Coordinators will have responsibility for managing all Joint Patent Rights claiming Joint Know-How as set forth in Section 9.4.1.
9.4 Patent Filing, Prosecution and Maintenance.
9.4.1 Patent Filing, Prosecution and Maintenance of Joint Patent Rights. The Parties, acting through the Patent Coordinators, shall be jointly responsible for preparing, filing, prosecuting, obtaining and maintaining all Joint Patent Rights. The Parties will share equally the expense of such efforts; provided, however, that either Party may decide not to share such expenses, on a country-by-country basis, and thereafter such Joint Patent Rights, in such country, shall be deemed to be exclusively owned by the other Party. The Parties shall jointly select patent attorneys and agents to assist them in such efforts.
9.4.2 Patent Filing, Prosecution and Maintenance by EPIX. Subject to the other terms of this Section 9, EPIX shall be responsible for preparing, filing, prosecuting, obtaining and maintaining, at its sole cost, expense and discretion, and acting through patent attorneys or agents of its choice, all EPIX Patent Rights. With regard to those EPIX Patent Rights relevant to the actual research projects being conducted during the Research Program Term EPIX: (i) will keep the Patent Coordinators reasonably informed of the status of such filing, prosecution and maintenance, including, without limitation: (a) by providing the Patent Coordinators with copies of all communications received from or filed in patent office(s) with respect to such filing, and (b) by providing the Patent Coordinators a reasonable time prior to taking or failing to take any action that would affect the scope or validity of any such of any such filing (including the substantially narrowing, cancellation or abandonment of any claim(s) without retaining the right to pursue such subject matter in a separate application, or the failure to file or perfect the filing of any claim(s) in any country), with prior written notice of such proposed action or inaction so that the Patent Coordinators have a reasonable opportunity to review and comment.
9.4.3 Patent Filing, Prosecution and Maintenance by SCHERING. Subject to the other terms of this Section 9, SCHERING shall be responsible for preparing, filing, prosecuting, obtaining and maintaining, at its sole cost, expense and discretion, and acting through patent attorneys or agents of its choice, all SCHERING Patent Rights. With regard to those SCHERING Patent Rights relevant to the actual research projects being conducted during the Research Program Term SCHERING will keep the Patent Coordinators reasonably informed of the status of such filing, prosecution and maintenance, including, without limitation: (a) by
24
providing the Patent Coordinators with copies of all communications received from or filed in patent office(s) with respect to such filing, and (b) by providing the Patent Coordinators a reasonable time prior to taking or failing to take any action that would affect the scope or validity of any such of any such filing (including the substantially narrowing, cancellation or abandonment of any claim(s) without retaining the right to pursue such subject matter in a separate application, or the failure to file or perfect the filing of any claim(s) in any country), with prior written notice of such proposed action or inaction so that the Patent Coordinators have a reasonable opportunity to review and comment.
9.5 Infringement of Patent Rights.
9.5.1 Infringement of Joint Patent Rights. The Parties shall jointly determine whether to bring suit (or take other appropriate legal action) against any actual, alleged or threatened infringement of Joint Patent Rights. If both Parties desire to take such action, they shall jointly determine how to share the expense and proceeds, if any, of the action and they shall jointly choose legal counsel. If either Party declines to take any such action, the other Party shall have the right (but not the obligation), at its own expense, to bring suit (or take other appropriate legal action) against such actual, alleged or threatened infringement, with legal counsel of its own choice, but shall not be permitted to settle any such suit without the prior consent of the other Party, which consent shall not be unreasonably withheld. Any damages, monetary awards or other amounts recovered, whether by judgment or settlement, pursuant to any suit, proceeding or other legal action taken by a single Party under this Section shall applied as follows:
(a) First, to reimburse the Party bringing such action for it’s costs and expenses (including reasonable attorneys’ fees and costs) incurred in prosecuting such enforcement action;
(b) Second, the remainder shall be divided between the Parties with [*****] to the Party bringing such action and the remaining [*****] to the other Party.
9.5.2 Infringement of EPIX Patent Rights. EPIX shall have the first right (but not the obligation), at its own expense and with legal counsel of its own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or threatened infringement of EPIX’ Patent Rights in the Field. SCHERING shall have the right, at its own expense, to be represented in any such action by EPIX by counsel of XXXXXXXX’s own choice; provided, however, that under no circumstances shall the foregoing affect the right of EPIX to control the suit as described in the first sentence of this Section. If EPIX does not file any action or proceeding against such infringement within six (6) months after the later of (i) EPIX’s notice to SCHERING under Section 9.5.4, (ii) SCHERING’s notice to EPIX under Section 9.5.4, or (iii) a written request from SCHERING to take action with respect to such infringement, then SCHERING shall have the right (but not the obligation), at its own expense, to bring suit (or take other appropriate legal action) against such actual, alleged or threatened infringement, with legal counsel of its own choice, but shall not be permitted to settle any such suit without the prior consent of EPIX, which consent shall not be unreasonably withheld. Any damages, monetary awards or other amounts recovered, whether by judgment or settlement, pursuant to any suit,
25
proceeding or other legal action taken under this Section 9.5, shall applied as follows:
(a) First, to reimburse the Parties for their respective costs and expenses (including reasonable attorneys’ fees and costs) incurred in prosecuting such enforcement action;
(b) Second, to licensing Party in reimbursement for lost sales (net of royalties) associated with Licensed Products and to the licensor Party in reimbursement for lost royalties owing hereunder based on such lost sales;
(c) Third, any amounts remaining shall be allocated as follows: (a) if EPIX is the Party bringing such suit or proceeding or taking such other legal action, one hundred percent (100%) to EPIX, (b) if SCHERING is the Party bringing such suit or proceeding or taking such other legal action, one hundred percent (100%) to SCHERING, and (c) if the suit is brought jointly, fifty percent (50%) to each Party.
9.5.3 Infringement of SCHERING Patent Rights. SCHERING shall have the first right (but not the obligation), at its own expense and with legal counsel of its own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or threatened infringement of XXXXXXXX’s Patent Rights. EPIX shall have the right, at its own expense, to be represented in any such action by SCHERING by counsel of EPIX’s own choice; provided, however, that under no circumstances shall the foregoing affect the right of SCHERING to control the suit as described in the first sentence of this Section 9.5.3. If SCHERING does not file any action or proceeding against such infringement within six (6) months after the later of (i) SCHERING’s notice to EPIX under Section 9.5.4, (ii) EPIX’s notice to SCHERING under Section 9.5.4, or (iii) a written request from EPIX to take action with respect to such infringement, then EPIX shall have the right (but not the obligation), at its own expense, to bring suit (or take other appropriate legal action) against such actual, alleged or threatened infringement, with legal counsel of its own choice, but shall not be permitted to settle any such suit without the prior consent of SCHERING, which consent shall not be unreasonably withheld. Any damages, monetary awards or other amounts recovered, whether by judgment or settlement, pursuant to any suit, proceeding or other legal action taken under this Section 9.5, shall applied as follows:
(a) First, to reimburse the Parties for their respective costs and expenses (including reasonable attorneys’ fees and costs) incurred in prosecuting such enforcement action;
(b) Second, to licensing Party in reimbursement for lost sales (net of royalties) associated with Licensed Products and to the licensor Party in reimbursement for lost royalties owing hereunder based on such lost sales;
(c) Third, any amounts remaining shall be allocated as follows: (a) if SCHERING is the Party bringing such suit or proceeding or taking such other legal action, one hundred percent (100%) to SCHERING, (b) if EPIX is the Party bringing such suit or proceeding
26
or taking such other legal action, one hundred percent (100%) to EPIX, and (c) if the suit is brought jointly, fifty percent (50%) to each Party.
9.5.4 Notice of Infringement. If either Party learns of any actual, alleged or threatened infringement by a Third Party of any Patent Rights related to the Research Program or any license granted under this Agreement(that is EPIX Patent Rights, SCHERING Patent Rights and Joint Patent Rights), such Party shall promptly notify the other Party and shall provide such other Party with available evidence of such infringement.
9.5.5 Infringement of Know-How. Section 9.5 and the principles and mechanisms set forth therein shall apply accordingly to any infringement of unpatented Know-How related to the Research Program or any license granted under this Agreement (that is EPIX Know-How, SCHERING Know-How and Joint Know-How.
9.6 Cooperation. If a Party brings any such action or proceeding hereunder, the other Party agrees to be joined as party plaintiff if necessary to prosecute such action or proceeding, and to give the Party bringing such action or proceeding reasonable assistance and authority to file and prosecute the suit; provided, however, that neither Party shall be required to transfer any right, title or interest in or to any property to the other Party or any Third Party to confer standing on a Party hereunder.
9.7 Patent Management. The Parties agree to exercise their respective rights to manage the filing, prosecution and maintenance of Patent Rights under this Agreement in a manner, insofar as reasonably possible, that maximizes the value of such Patent Rights within the Field.
10. CONFIDENTIALITY
10.1 Nondisclosure Obligations.
10.1.1 General. Except as provided in this Article 10, during the Term and for a period of fifteen (15) years thereafter, both Parties shall maintain in confidence and use only for purposes specifically authorized under this Agreement: (i) information and data received from the other Party resulting from or related to Know-How, the development of Lead Compounds, Development Candidates and Licensed Products and (ii) all information and data not described in clause (i) but supplied by the other Party under this Agreement marked “Confidential.” For purposes of this Article10, information and data described in clause (i) or (ii) shall be referred to as “Information.”
10.1.2 Limitations. To the extent it is reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this Agreement, a Party may disclose Information it is otherwise obligated under this Section 10.1 not to disclose to its Affiliates, sublicensees, consultants, outside contractors and clinical investigators, on a need-to-know basis on condition that such entities or persons enter into written agreements to keep the Information confidential for the same time periods and to the same extent as such Party is required to keep
27
the Information confidential. In addition a Party or its Affiliates or sublicensees may disclose such Information to government or other regulatory authorities to the extent that such disclosure is reasonably necessary to obtain patents or authorizations to conduct clinical trials of, and to commercially market Licensed Products. However, for the avoidance of doubt, the Parties state that neither SCHERING nor EPIX shall disclose pre-clinical or clinical data of the contents or pre-clinical or clinical study, reports derived from studies of Licensed Products that has been received from the other Party to advertising agencies, marketing research consultants, customers, healthcare professionals, consumers or regulatory agencies without the prior written approval of the other Party.
The obligation not to disclose Information shall not apply to any part of such Information that: (i) is or becomes part of the public domain other than by unauthorized acts of the Party obligated not to disclose such Information or those of its Affiliates or Sublicensees; (ii) can be shown by competent evidence to have been disclosed to the receiving Party or its or Sublicensees by a Third Party, provided, that such Information was not obtained by such Third Party directly or indirectly from the other Party under this Agreement pursuant to a confidentiality agreement; (iii) can be shown by competent evidence, prior to disclosure under this Agreement, to already have been in the possession of the receiving Party or its Affiliates or Sublicensees, provided, that such Information was not obtained directly or indirectly from the other Party under this Agreement pursuant to a confidentiality agreement; (iv) can be shown by competent evidence to have been independently developed by the receiving Party or its Affiliates without breach of any of the provisions of this Agreement; or (v) is disclosed by the receiving Party pursuant to interrogatories, requests for information or documents, subpoena, civil investigative demand issued by a court or governmental agency or as otherwise required by law; provided, that, the receiving Party notifies the other Party immediately upon receipt thereof so that such other Party (with the cooperation of the receiving Party) can seek a protective order or other order limiting or preventing disclosure; and provided, further, that the disclosing Party furnishes only that portion of the Information which it is advised by counsel is legally required under the circumstances.
10.1.3 Terms of this Agreement. Except as provided in Section 10.1.2 hereof, EPIX and SCHERING each agree not to disclose any terms or conditions of this Agreement to any Third Party without the prior written consent of the other Party, except as required by applicable law. If either Party determines that it is required to file this Agreement with the Securities and Exchange Commission or other governmental agency for any reason, such Party shall request confidential treatment of such portions of this Agreement as the Parties shall together determine is appropriate. Notwithstanding the foregoing, prior to execution of this Agreement, EPIX and SCHERING have agreed upon the substance of information that can be used as a routine reference in the usual course of business to describe the terms of this transaction, and EPIX and SCHERING may disclose such information, as modified by mutual agreement from time to time, without the other Party’s consent as may be necessary from time to time.
10.2 Injunctive Relief. The Parties hereto understand and agree that remedies at law may be inadequate to protect against any breach of any of the provisions of this Article 10 by
28
either Party or their employees, agents, officers or directors or any other person acting in concert with it or on its behalf. Accordingly, each Party shall be entitled to the granting of injunctive relief or other equitable relief by a court of Competent jurisdiction against any action that constitutes any such breach of this Article 10, in addition to any monetary damages to which a Party may be entitled.
11. REPRESENTATIONS AND WARRANTIES
11.1 Representations and Warranties. EPIX and SCHERING each represent and warrant to the other, as of the Effective Date as follows:
11.2 Organization. It is a corporation duly organized, validly existing and is in good standing under the laws of the jurisdiction of its organization, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the performance of its obligations hereunder requires such qualification and has all requisite power and authority, corporate or otherwise, to conduct its business as now being conducted, to own, lease and operate its properties and to execute, deliver and perform this Agreement.
11.3 Authorization. The execution, delivery and performance by it of this Agreement: (a) have been duly authorized by all necessary corporate action and (b) do not and will not violate any provision of any agreement, law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect having applicability to it or any provision of its charter documents.
11.4 No Inconsistent Obligation. It is not under any obligation to any person, or entity, contractual or otherwise, that is conflicting or inconsistent in any respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder and that it has all power and authority under all instruments or agreements to which it is a Party to enter into this Agreement and to perform its obligations hereunder.
11.5 Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.
12. INDEMNITY
12.1 Claim. For purposes of this Article 12 “Claim” shall mean any and all Third Party suits, actions, claims, demands, liabilities, expenses, and/or losses, including without limitation reasonable attorneys fees, based upon, arising in connection with, or resulting from the development, clinical study in humans, or commercialization of Lead Compounds, Development Candidates and Licensed Products excluding any suits, actions, claims, demands, liabilities, expenses, and/or losses based upon, arising in connection with, or resulting from infringement of
29
the intellectual property rights (including without limitation patent rights) of any Third Party or Third Parties.
12.2 SCHERING Indemnity Obligations. Subject to the provisions of Sections 12.3 and 12.4, XXXXXXXX agrees to defend, indemnify and hold EPIX, its Affiliates and their respective directors, officers, employees and agents harmless from all Claims against EPIX, its Affiliates or their respective directors, officers, employees or agents solely based upon, arising in connection with or resulting from (a) actual or asserted violations of any applicable law or regulation by SCHERING, its Affiliates, sublicensees, or agents by virtue of which any Lead Compound, Development Candidate, or Licensed Product is developed, distributed or sold by SCHERING shall be alleged or determined to be adulterated, misbranded, mislabeled or otherwise not in compliance with such applicable law or regulation, (b) the manufacture, use, sale or promotion of Lead Compounds, Development Candidates or Licensed Products by SCHERING; (c) any negligent or willful or intentional act or omission to act by SCHERING, its Affiliates, sublicensees, or agents in any manner in connection with performance hereunder; or (d) the breach of any representation or warranty of SCHERING in this Agreement.
12.3 EPIX Indemnity Obligations. Subject to the provisions of Sections 12.2 and 12.4, EPIX agrees to defend, indemnify and hold SCHERING, its Affiliates and their respective directors, officers, employees and agents harmless from all Claims against SCHERING, its Affiliates or their respective directors, officers, employees or agents solely based upon, arising in connection with or resulting from (a) actual or asserted violations of any applicable law or regulation by EPIX, its Affiliates, sublicensees, or agents by virtue of which any Lead Compound, Development Candidate, or Licensed Product is developed, distributed or sold by EPIX shall be alleged or determined to be adulterated, misbranded, mislabeled or otherwise not in compliance with such applicable law or regulation, (a) the manufacture, use, sale or promotion of Lead Compounds, Development Candidates or Licensed Products; (b) any negligent or willful or intentional act or omission to act by EPIX, its Affiliates, sublicensees or agents in any manner in connection with performance hereunder; or (c) the breach of any representation or warranty of EPIX in this Agreement.
12.4 Procedure. A Party or any of its Affiliates (the “Indemnitee”) that intends to claim indemnification under this Sections 12.2 or 12.3 shall promptly notify the other Party (the “Indemnitor”) of the Claim in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall assume the defense thereof with counsel mutually ‘satisfactory to the Parties; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such Indemnitee by the counsel retained by the Indemnitor, would be inappropriate due to actual or potential differing interests between such Indemnitee and any other Party represented by such counsel in such proceedings. An Indemnitee shall not be entitled to indemnification under Sections 12.2 or 12.3 if any settlement or compromise of a Claim is effected by the Indemnitee without the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed. The failure to deliver notice to the Indemnitor within a reasonable time after notice of a Claim, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any
30
liability to the Indemnitee under Sections 12.2 or 12.3. The Indemnitee under Sections 12.2 or 12.3, its employees and agents (and those of any indemnified Affiliates or other Indemnitees), shall cooperate fully with the Indemnitor and its legal representatives in the investigation and defense of the Claim covered by this indemnification. Any Costs paid by an Indemnitor shall be without prejudice to the Indemnitor’s right to contest the Indemnitee’s right to be indemnified, and subject to refund in the event that the Indemnitor is ultimately held not to be obligated to indemnify the Indemnitee.
12.5 Limited Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, NEITHER EPIX NOR SCHERING WILL BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR LOST PROFITS.
13. MISCELLANEOUS
13.1 Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including but not limited to fire, floods, embargoes, war, acts of war (whether war is declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental authority; provided, however, that the Party so affected shall use reasonable commercial efforts to avoid or remove such causes of nonperformance, and shall continue performance hereunder with reasonable dispatch whenever such causes are removed. Either Party shall provide the other Party with prompt written notice of any delay or failure to perform that occurs by reason of force majeure. The Parties shall mutually seek a resolution of the delay or the failure to perform as noted above.
13.2 Assignment. This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party; provided, however, that either EPIX or SCHERING may, without such consent, assign its rights and obligations under this agreement: (i) to any Affiliate, or (ii) in connection with a merger, consolidation or sale of substantially all of such Party’s assets to an unrelated Third Party; provided, however, with respect to this Subsection (ii), that the other Party has the right to terminate with immediate effect the Research Program Term under this Agreement; provided, further, with respect to this Subsection (ii), that such Party’s rights and obligations under this Agreement shall be assumed in writing by its successor in interest in any such transaction and shall not be transferred separately from all or substantially all of its diagnostic imaging business assets. Any purported assignment in violation of the preceding sentence shall be void. Any permitted assignee shall assume all obligations of its assignor under this Agreement.
13.3 Severability. Each Party hereby agrees that it does not intend, by its execution hereof, to violate any public policy, statutory or common laws, rules, regulations, treaty or
31
decision of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become invalid, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid provisions which valid provisions in their economic and other effects are sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the invalidity of one or several provisions of this Agreement shall not affect the validity of this Agreement as a whole or the validity of any portions hereof, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid provisions.
13.4 Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the Parties hereto to the other shall be in writing, delivered personally or by courier, postage prepaid (where applicable), addressed to such other Party at its address indicated below, or to such other address as the addressee shall have last furnished in writing to the addressor and shall be effective upon receipt by the addressee.
If to EPIX: EPIX Medical, Inc.
00 Xxxxxx Xxxxxx
Cambridge, Massachusetts 02142-1118
Attention: Chief Executive Officer
with a copy to: Xxxxx Xxxxx, Xxxx, Xxxxxx, Xxxxxxx and Xxxxx, P.C.
One Financial Center
Boston, Massachusetts 02111
Attention: Xxxxxxx X. Xxxxxx, Esq.
If to SCHERING: SCHERING Aktiengesellschaft
13342 Berlin
Germany
Attention: Head of Corporate Research
with a copy to: SCHERING Aktiengesellschaft
13342 Berlin
Germany
Attention: Legal Department
13.5 Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to the choice of laws provisions thereof.
13.6 General Dispute Resolution.
13.6.1 Negotiation. Subject to any other dispute resolution principles and mechanisms set forth in this Agreement, the Parties hereby agree that they will attempt in good
32
faith to, resolve any controversy or claim arising out of or relating to this Agreement promptly by negotiations. If a controversy or claim should arise hereunder, the representatives of the Parties will confer at least once and will attempt to resolve the matter. If the matter has not been resolved within fourteen (14) Business Days of their first meeting, the representatives shall refer the matter to the Chief Executive Officer of EPIX and the Head of Corporate Research of SCHERING. If the matter has not been resolved within thirty (30) Business Days of the first meeting of the Chief Executive Officer of EPIX and the Head of Corporate Research of SCHERING (which period may be extended by mutual agreement), subject to rights to injunctive relief and specific performance, and unless otherwise specifically provided for herein, any controversy or claim arising out of or relating to this Agreement, or the breach thereof, will be settled as set forth in Section 13.6.2, unless provided otherwise in this Agreement.
13.6.2 Arbitration. All disputes, controversies or differences which may arise between the Parties out of or in relation to this Agreement or any default or breach thereof may be resolved by arbitration in accordance with the commercial arbitration rules (except as otherwise specified herein) of the American Arbitration Association by three arbitrators, one to be selected by each of the Parties from a list of arbitrators supplied by the American Arbitration Association within thirty days of receipt of such list, and a third to be selected by the first two from such list within a reasonable time. The arbitrators shall be experienced in the subject matter of the arbitration (for example, arbitration of a scientific issue would require appointment of arbitrators with knowledge of the relevant area of science). The arbitration shall take place in New York, New York. Either Party may initiate an arbitration by written not ice to the other Party, such notice shall set forth the particulars of the issue to be arbitrated in sufficient detail to permit the Party receiving the notice to conduct an investigation and formulate a position (such notice shall not preclude the Parties from attempting to informally settle their differences). The arbitrators shall select one of their number to serve as presiding arbitrator, with the responsibility for handling administrative matters relating to the arbitration. Within sixty days of written notice to the Parties of the selection of the third arbitrator, each Party shall contemporaneously submit in writing to the presiding arbitrator and the other Party its position for the resolution of the issue that is the subject matter of the arbitration. At the request of either Party, to be submitted to the presiding arbitrator and the other Party within sixty days receipt of the written position of the other Party, the arbitrators shall schedule in-person presentations of the Parties (at which both parties and all three arbitrators shall be present), which may include the presentation of witnesses, oral argument, or both, at the discretion of each of the Parties, and which shall not exceed five hours for each of the Parties. The in-person presentations shall be scheduled by the arbitrators at their convenience and the reasonable convenience of the Parties, but shall be held within ninety and one hundred fifty days of receipt by the presiding arbitrator of the first request for an in-person presentation. If neither Party makes a request for an in person presentation, then the decision of the arbitrators shall be based solely on the written positions of the Parties. The arbitrators shall have the power only to select one of the Party’s positions, and the decision of any two of the arbitrators shall be the result of the arbitration. The non-prevailing Party shall bear the costs of the arbitration. The decision resulting from the arbitration provided for herein shall be final and binding on the Parties hereto. Notwithstanding the above, without resort to arbitration in the first instance, either Party has the right to bring suit against the other Party for:
33
(i) any breach of such other Party’s duties of confidentiality pursuant to Article 10 of this Agreement and (ii) any infringement of its own proprietary rights by the other Party. Judgment upon the arbitrators’ award may be entered in any court of competent jurisdiction. The Parties agree not to institute any litigation or proceedings against each other in connection with this Agreement unless they have complied with the provisions of this Section 13.6.2, as they may be applicable, unless otherwise provided herein.
13.7 Public Announcements. Anything in Article 10 to the contrary notwithstanding, the Parties agree that press releases and other announcements to be made by either of them in relation to this Agreement shall be subject to the written consent of the other Party, which consent shall not be unreasonably withheld or delayed, except to the extent that any such press release is required to be made by law or the rules of any national stock exchange and the consent of the other Party is not obtained after reasonable efforts to do so. The Parties will agree to issue a joint press release immediately following the execution of this Agreement, the form and content of which shall be reasonably satisfactory to both Parties.
13.8 Entire Agreement; Amendment. This Agreement, together with the exhibits hereto, contain the entire understanding of the Parties with respect to the subject matter hereof. All express or implied agreements and understandings, either oral or written, heretofore made are expressly merged in and made a part of this Agreement and the other agreements described in this Section. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by both Parties hereto.
13.9 Headings. The captions to the several Articles and Sections hereof are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof.
13.10 Agreement Not to Solicit Employees. During the Term and for a period of two (2) years following the expiration or termination of this Agreement, EPIX and SCHERING agree not to seek to persuade or induce any employee of the other company to discontinue his or her employment with that company in order to become employed by or associated with any business, enterprise or effort that is associated with its own business.
13.11 Exports. The Parties acknowledge that the export of technical data, materials or products is subject to the exporting Party receiving any necessary export licenses and that the Parties cannot be responsible for any delays attributable to export controls which are beyond the reasonable control of either Party. EPIX and SCHERING agree not to export or re-export, directly or indirectly, any information, technical data, the direct product of such data, samples or equipment received or generated under this Agreement in violation of any applicable export control laws or governmental regulations. EPIX and SCHERING agree to obtain similar covenants from their licensees, Sublicensees and contractors with respect to the subject matter of this Section 13.11.
13.12 Waiver. The waiver by either Party hereto of any right hereunder shall not be
34
deemed a waiver of any other right hereunder whether of a similar nature or otherwise.
13.13 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
13.14 Independent Contractors; Negation of Partnership. The relationship of EPIX and SCHERING established by this Agreement is that of independent contractors, and nothing contained in this Agreement shall be construed to give either Party the power to direct or control the day-to-day activities of the other, or allow one Party to create or assume an obligation on behalf of the other Party for any purpose whatsoever. This Agreement is not intended to create a partnership between EPIX and SCHERING for United States federal income tax purposes (as defined in Section 761 of the Internal Revenue Code), for any state or local jurisdiction in the United States, of for any country other than the United States. Therefore, there is no requirement in the United States to file Form 1065, United States Partnership Return of Income, or any similar state or local income tax return in any political subdivision of the United States, or any similar tax document in any country other than the United States, in regard to the contractual relationship described in this Agreement.
13.15 Ambiguities. The Parties acknowledge and agree that: (i) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.
IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.
|
EPIX MEDICAL, INC. |
||
|
|
|
|
|
|
|
|
|
By: |
|
|
|
|
Xxxxxxx X. Xxxx |
|
|
|
Chief Executive Officer |
|
35
|
SCHERING AKTIENGESELLSCHAFT |
||
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
Prof. Xx. Xxxxxx Xxxxx |
|
|
|
Member of the Vorstand |
|
|
|
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
Prof. Xx. Xxxxx Xxxxxxxx |
|
|
|
Head of Corporate Research |
|
36
EPIX Patent Rights
The following patent families constitute existing utility applications assigned to EPIX or in the case of the MET-1 patent family exclusively licensed from The General Hospital Corporation of Boston, Massachusetts (Agreement of March 24, 1992 amended July 10, 1995). MET-9 is assigned to Dyax and EPIX with EPIX having exclusive rights to MRI applications (Agreement of June 20, 1997 amended March 17, 2003).
|
MET-1 |
|
US |
|
[*****] |
|
|
|
US-CIP |
|
[*****] |
|
|
|
PCT |
|
[*****] |
|
|
|
EPO |
|
[*****] |
|
|
|
CANADA |
|
[*****] |
|
|
|
HONG KONG |
|
[*****] |
|
|
|
LATVIA |
|
[*****] |
|
|
|
SINGAPORE |
|
[*****] |
|
|
|
|
|
|
|
MET-3 |
|
US |
|
[*****] |
|
|
|
PCT |
|
[*****] |
|
|
|
|
|
|
|
MET-4 |
|
PCT |
|
[*****] |
|
|
|
AUSTRALIA |
|
[*****] |
|
|
|
ISRAEL |
|
[*****] |
|
|
|
NEW ZEALAND |
|
[*****] |
|
|
|
SINGAPORE |
|
[*****] |
|
|
|
SOUTH AFRICA |
|
[*****] |
|
|
|
SWAZILAND |
|
[*****] |
|
|
|
TAIWAN |
|
[*****] |
|
|
|
|
|
|
|
MET-5 |
|
US CON Publication |
|
[*****] |
|
|
|
PCT |
|
[*****] |
|
|
|
EPO |
|
[*****] |
|
|
|
AUSTRALIA |
|
[*****] |
|
|
|
CHINA |
|
[*****] |
|
|
|
ISRAEL |
|
[*****] |
|
|
|
NEW ZEALAND |
|
[*****] |
|
|
|
SINGAPORE |
|
[*****] |
|
|
|
|
|
|
|
MET-6 |
|
US |
|
[*****] |
|
|
|
AUSTRALIA |
|
[*****] |
37
|
|
|
NEW ZEALAND |
|
[*****] |
|
|
|
|
|
|
|
MET-7 |
|
AUSTRALIA |
|
[*****] |
|
|
|
EPO |
|
[*****] |
|
|
|
NEW ZEALAND |
|
[*****] |
|
|
|
|
|
|
|
MET-8 |
|
US |
|
[*****] |
|
|
|
PCT |
|
[*****] |
|
|
|
|
|
|
|
MET-9 |
|
US Application |
|
[*****] |
|
|
|
PCT |
|
[*****] |
|
|
|
|
|
|
|
MET-10 |
|
US |
|
[*****] |
|
|
|
PCT |
|
[*****] |
|
|
|
|
|
|
|
MET-11 |
|
PCT |
|
[*****] |
|
|
|
|
|
|
|
MET-12 |
|
US |
|
[*****] |
|
|
|
PCT |
|
[*****] |
|
|
|
|
|
|
|
MET-14 |
|
PCT |
|
[*****] |
|
|
|
|
|
|
|
MET-15 |
|
PCT |
|
[*****] |
|
|
|
|
|
|
|
MET-16 |
|
US Publication |
|
[*****] |
|
|
|
PCT |
|
[*****] |
38
Products of SCHERING in Development or Commercialized
1. Commercialized Products
Magnevist (gadopentetate dimeglumine)
Gadovist (gadobutrol)
Resovist (ferucarbotran)
Feridex (ferumoxide)
Teslascan (mangafodipir trisodium)
2. Products in Development
[*****]
39
Schering Patent Rights
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
02346A |
|
NL |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
NL |
|
[*****] |
|
[*****] |
|
04/FEB/2003 |
|
02346A |
|
NO |
|
|
|
[*****] |
|
23/JUL/2002 |
|
02346A |
|
NO |
|
[*****] |
|
[*****] |
|
05/FEB/2003 |
|
02346A |
|
SE |
|
[*****] |
|
[*****] |
|
07/SEP/2004 |
|
02346A |
|
NL |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
IT |
|
[*****] |
|
[*****] |
|
31/DEC/2007 |
|
02346A |
|
JP |
|
|
|
[*****] |
|
23/JUL/2002 |
|
02346A |
|
LU |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
GB |
|
[*****] |
|
[*****] |
|
04/FEB/2003 |
|
02346A |
|
GB |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
GB |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
FR |
|
[*****] |
|
[*****] |
|
21/JUN/2005 |
|
02346A |
|
FR |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
FR |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
IT |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
LU |
|
[*****] |
|
[*****] |
|
05/FEB/2003 |
|
02346A |
|
LU |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
DE |
|
[*****] |
|
[*****] |
|
05/FEB/2003 |
|
02346A |
|
DE |
|
|
|
[*****] |
|
24/JUL/2001 |
|
02346A |
|
DE 0071564 |
|
[*****] |
|
[*****] |
|
|
|
02346A |
|
DE |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
CH |
|
[*****] |
|
[*****] |
|
19/SEP/2003 |
|
02346A |
|
CH |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
CH |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
IE |
|
|
|
[*****] |
|
03/FEB/2003 |
|
02346A |
|
IE |
|
|
|
[*****] |
|
23/JUL/2002 |
|
02346A |
|
AT |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
AT |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
CA |
|
|
|
[*****] |
|
16/AUG/2005 |
|
02346A |
|
BE |
|
[*****] |
|
[*****] |
|
|
|
02346A |
|
BE |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
BE |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
AU |
|
|
|
[*****] |
|
22/JUL/2007 |
|
02346A |
|
AU |
|
|
|
[*****] |
|
22/JUL/2002 |
|
02346A |
|
AU |
|
[*****] |
|
[*****] |
|
22/JUL/2002 |
|
02346A |
|
AT |
|
[*****] |
|
[*****] |
|
05/FEB/2003 |
|
02346A |
|
CA |
|
[*****] |
|
[*****] |
|
03/MAR/2004 |
|
02346A |
|
JP |
|
|
|
[*****] |
|
23/JUL/2002 |
|
02346A |
|
JP |
|
|
|
[*****] |
|
23/JUL/2002 |
|
02346A |
|
IT |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
ZA |
|
|
|
[*****] |
|
23/JUL/2002 |
|
02346A |
|
SE |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
SE |
|
[*****] |
|
[*****] |
|
19/JUL/2002 |
|
02346A |
|
NZ |
|
|
|
[*****] |
|
23/JUL/2002 |
40
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
02491A |
|
US |
|
|
|
[*****] |
|
01/OCT/2013 |
|
02491A |
|
US |
|
|
|
|
|
|
|
02491A |
|
US |
|
|
|
[*****] |
|
04/JUN/2008 |
|
02491A |
|
US |
|
|
|
[*****] |
|
03/MAR/2004 |
|
02491A |
|
US |
|
|
|
[*****] |
|
02/MAR/2004 |
|
02491A |
|
US |
|
|
|
[*****] |
|
08/NOV/2011 |
|
02491A |
|
US |
|
|
|
[*****] |
|
02/MAR/2004 |
|
02491A |
|
SE |
|
[*****] |
|
|
|
19/JAN/2004 |
|
02491A |
|
SG |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
JP |
|
|
|
[*****] |
|
18/JAN/2004 |
|
02491A |
|
JP |
|
|
|
[*****] |
|
|
|
02491A |
|
IT |
|
|
|
[*****] |
|
19/JAN/2004 |
|
02491A |
|
IL |
|
|
|
[*****] |
|
18/JAN/2004 |
|
02491A |
|
NZ |
|
|
|
[*****] |
|
18/JAN/2004 |
|
02491A |
|
US |
|
|
|
|
|
|
|
02491A |
|
US |
|
|
|
|
|
|
|
02491A |
|
US |
|
|
|
[*****] |
|
02/MAR/2004 |
|
02491A |
|
SG |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
GB |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
FR |
|
[*****] |
|
[*****] |
|
19/XXX/2004 |
|
02491A |
|
FR |
|
[*****] |
|
[*****] |
|
19/XXX/2004 |
|
02491A |
|
IL |
|
|
|
[*****] |
|
18/JAN/2004 |
|
02491A |
|
NZ |
|
|
|
[*****] |
|
18/JAN/2004 |
|
02491A |
|
NO |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
NL |
|
[*****] |
|
[*****] |
|
10/XXX/2004 |
|
02491A |
|
NL |
|
|
|
|
|
10/JAN/2004 |
|
02491A |
|
LU |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
BE |
|
|
|
[*****] |
|
19/JAN/2004 |
|
02491A |
|
AU |
|
[*****] |
|
[*****] |
|
18/JAN/2004 |
|
02491A |
|
AU |
|
[*****] |
|
[*****] |
|
18/JAN/2004 |
|
02491A |
|
FI |
|
[*****] |
|
[*****] |
|
19/XXX/2004 |
|
02491A |
|
IE |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
IE |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
GR |
|
|
|
[*****] |
|
19/JAN/2004 |
|
02491A |
|
GB |
|
[*****] |
|
|
|
20/JAN/2004 |
|
02491A |
|
GB |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
AT |
|
|
|
[*****] |
|
15/SEP/2011 |
|
02491A |
|
ES |
|
|
|
[*****] |
|
22/NOV/2004 |
|
02491A |
|
DK |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
DK |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
CH |
|
|
|
[*****] |
|
20/JAN/2004 |
|
02491A |
|
CA |
|
|
|
[*****] |
|
20/JUN/2006 |
|
02491A |
|
SE |
|
[*****] |
|
[*****] |
|
19/JAN/2004 |
|
02491A |
|
PT |
|
|
|
[*****] |
|
09/APR/2004 |
|
02491A |
|
US |
|
|
|
|
|
|
|
02491A |
|
US |
|
|
|
|
|
|
|
02491A |
|
US |
|
|
|
|
|
|
|
02491A |
|
US |
|
|
|
[*****] |
|
03/JUN/2008 |
|
02491A |
|
ZA |
|
|
|
[*****] |
|
20/JAN/2004 |
41
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
02491A |
|
SG |
|
|
|
|
|
20/JAN/2004 |
|
02491A |
|
SG |
|
|
|
|
|
20/JAN/2004 |
|
02575A |
|
DE |
|
|
|
[*****] |
|
11/JAN/2004 |
|
02575A |
|
DE |
|
[*****] |
|
[*****] |
|
11/XXX/2004 |
|
02969A |
|
AT |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
AU |
|
[*****] |
|
[*****] |
|
27/JUL/2007 |
|
02969A |
|
BE |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
CA |
|
|
|
[*****] |
|
30/JAN/2018 |
|
02969A |
|
CH |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
DE |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
DE |
|
|
|
[*****] |
|
28/JUL/2006 |
|
02969A |
|
DK |
|
|
|
[*****] |
|
28/JUL/2007 |
|
02969A |
|
ES |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
FR |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
GB |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
GR |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
IE |
|
|
|
[*****] |
|
28/JUL/2007 |
|
02969A |
|
IT |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
JP |
|
|
|
[*****] |
|
28/JUL/2007 |
|
02969A |
|
LU |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
NL |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
NO |
|
|
|
[*****] |
|
27/JUL/2007 |
|
02969A |
|
NZ |
|
|
|
[*****] |
|
28/JUL/2007 |
|
02969A |
|
PT |
|
|
|
[*****] |
|
03/DEC/2007 |
|
02969A |
|
SE |
|
[*****] |
|
[*****] |
|
24/JUL/2007 |
|
02969A |
|
US |
|
|
|
|
|
|
|
02969A |
|
US |
|
|
|
[*****] |
|
16/FEB/2016 |
|
02969A |
|
US |
|
|
|
|
|
|
|
02969A |
|
US |
|
|
|
|
|
|
|
02969A |
|
US |
|
|
|
|
|
|
|
02969A |
|
US |
|
|
|
|
|
|
|
02969A |
|
ZA |
|
|
|
[*****] |
|
28/JUL/2007 |
|
03035A |
|
AT |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
AU |
|
[*****] |
|
[*****] |
|
27/NOV/2007 |
|
03035A |
|
AU |
|
|
|
|
|
|
|
03035A |
|
BE |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
CA |
|
|
|
[*****] |
|
14/SEP/2010 |
|
03035A |
|
CH |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
DE |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
DE |
|
|
|
[*****] |
|
28/NOV/2006 |
|
03035A |
|
DK |
|
|
|
[*****] |
|
10/NOV/2007 |
|
03035A |
|
ES |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
FR |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
GB |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
GR |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
IE |
|
|
|
[*****] |
|
27/NOV/2007 |
|
03035A |
|
IL |
|
|
|
[*****] |
|
25/NOV/2007 |
|
03035A |
|
IT |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
JP |
|
|
|
[*****] |
|
27/NOV/2007 |
42
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
03035A |
|
LU |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
NL |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
NO |
|
|
|
[*****] |
|
27/NOV/2007 |
|
03035A |
|
NZ |
|
|
|
[*****] |
|
25/NOV/2007 |
|
03035A |
|
PT |
|
|
|
[*****] |
|
06/MAR/2008 |
|
03035A |
|
SE |
|
[*****] |
|
[*****] |
|
23/NOV/2007 |
|
03035A |
|
US |
|
|
|
[*****] |
|
24/MAR/2009 |
|
03035A |
|
US |
|
|
|
|
|
|
|
03035A |
|
US |
|
|
|
[*****] |
|
02/MAR/2016 |
|
03035A |
|
US |
|
|
|
|
|
30/NOV/2007 |
|
03035A |
|
US |
|
|
|
|
|
|
|
03035A |
|
ZA |
|
|
|
[*****] |
|
27/NOV/2007 |
|
03193A |
|
DE |
|
[*****] |
|
[*****] |
|
27/FEB/2009 |
|
03193A |
|
JP |
|
|
|
[*****] |
|
|
|
03193A |
|
US |
|
|
|
[*****] |
|
28/OCT/2014 |
|
03193A |
|
US |
|
|
|
[*****] |
|
28/OCT/2014 |
|
03226A |
|
DE |
|
[*****] |
|
[*****] |
|
17/MAR/2009 |
|
03226A |
|
US |
|
|
|
[*****] |
|
08/FEB/2011 |
|
03226A |
|
US |
|
|
|
|
|
|
|
50116A |
|
DE |
|
[*****] |
|
[*****] |
|
11/AUG/2009 |
|
50116A |
|
US |
|
|
|
[*****] |
|
04/JAN/2011 |
|
50235A |
|
AT |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
AU |
|
[*****] |
|
[*****] |
|
29/JUN/2010 |
|
50235A |
|
BE |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
BY |
|
|
|
[*****] |
|
19/NOV/2013 |
|
50235A |
|
CA |
|
|
|
[*****] |
|
29/JUN/2010 |
|
50235A |
|
CH |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
CZ |
|
|
|
[*****] |
|
26/JUN/2010 |
|
50235A |
|
DD |
|
|
|
[*****] |
|
29/JUN/2008 |
|
50235A |
|
DE |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
DK |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
ES |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
FI |
|
|
|
[*****] |
|
29/JUN/2010 |
|
50235A |
|
FR |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
GB |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
GR |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
HK |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
HU |
|
|
|
[*****] |
|
29/JUN/2010 |
|
50235A |
|
IE |
|
|
|
[*****] |
|
26/JUN/2010 |
|
50235A |
|
IL |
|
|
|
[*****] |
|
21/JUN/2010 |
|
50235A |
|
IT |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
JP |
|
|
|
[*****] |
|
29/JUN/2010 |
|
50235A |
|
KR |
|
|
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
LU |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
NL |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
NO |
|
|
|
[*****] |
|
29/JUN/2010 |
|
50235A |
|
NZ |
|
[*****] |
|
[*****] |
|
28/JUN/2010 |
|
50235A |
|
PT |
|
|
|
[*****] |
|
25/NOV/2011 |
|
50235A |
|
RU |
|
|
|
[*****] |
|
29/JUN/2010 |
43
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
50235A |
|
SE |
|
[*****] |
|
[*****] |
|
27/JUN/2010 |
|
50235A |
|
SK |
|
|
|
[*****] |
|
26/JUN/2010 |
|
50235A |
|
TW |
|
|
|
[*****] |
|
08/NOV/2010 |
|
50235A |
|
UA |
|
|
|
[*****] |
|
28/JUN/2010 |
|
50235A |
|
US |
|
|
|
|
|
|
|
50235A |
|
US |
|
|
|
|
|
|
|
50235A |
|
US |
|
|
|
|
|
|
|
50235A |
|
US |
|
|
|
[*****] |
|
25/AUG/2015 |
|
50235A |
|
US |
|
|
|
[*****] |
|
21/MAR/2017 |
|
50235A |
|
US |
|
|
|
[*****] |
|
09/DEC/2014 |
|
50235A |
|
US |
|
|
|
|
|
|
|
50235A |
|
ZA |
|
|
|
[*****] |
|
29/JUN/2010 |
|
50298A |
|
AT |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
AU |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
BE |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
CA |
|
|
|
|
|
21/NOV/2010 |
|
50298A |
|
CH |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
DE |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
DK |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
ES |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
FI |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
FR |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
GB |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
GR |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
IE |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
IL |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
IT |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
JP |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
KR |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
LU |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
NL |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
NO |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
NZ |
|
[*****] |
|
[*****] |
|
20/NOV/2010 |
|
50298A |
|
PT |
|
|
|
[*****] |
|
22/SEP/2014 |
|
50298A |
|
SE |
|
[*****] |
|
[*****] |
|
19/NOV/2010 |
|
50298A |
|
US |
|
|
|
[*****] |
|
22/JUL/2014 |
|
50298A |
|
US |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
US |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
US |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
US |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
US |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
US |
|
|
|
|
|
21/NOV/2010 |
|
50298A |
|
US |
|
|
|
[*****] |
|
15/NOV/2011 |
|
50298A |
|
ZA |
|
|
|
[*****] |
|
21/NOV/2010 |
|
50298A |
|
US |
|
|
|
|
|
21/NOV/2010 |
|
50340A |
|
AT |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
AU |
|
[*****] |
|
[*****] |
|
19/MAR/2011 |
|
50340A |
|
AU |
|
|
|
[*****] |
|
19/MAR/2016 |
|
50340A |
|
BE |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
44
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
50340A |
|
BE |
|
[*****] |
|
[*****] |
|
24/JAN/2015 |
|
50340A |
|
CA |
|
|
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
CH |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
CH |
|
[*****] |
|
[*****] |
|
26/FEB/2013 |
|
50340A |
|
DE |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
DE |
|
|
|
[*****] |
|
24/JAN/2015 |
|
50340A |
|
DK |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
DK |
|
|
|
|
|
18/MAR/2016 |
|
50340A |
|
ES |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
FI |
|
|
|
[*****] |
|
19/MAR/2011 |
|
50340A |
|
FI |
|
|
|
|
|
19/MAR/2016 |
|
50340A |
|
FR |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
GB |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
GR |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
GR |
|
|
|
|
|
18/MAR/2016 |
|
50340A |
|
HK |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
HU |
|
|
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
IE |
|
|
|
[*****] |
|
19/MAR/2011 |
|
50340A |
|
IL |
|
|
|
[*****] |
|
19/MAR/2011 |
|
50340A |
|
IT |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
IT |
|
[*****] |
|
[*****] |
|
18/MAR/2016 |
|
50340A |
|
JP |
|
|
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
LU |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
NL |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
NO |
|
|
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
NO |
|
|
|
|
|
18/MAR/2016 |
|
50340A |
|
NZ |
|
|
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
|
|
[*****] |
|
[*****] |
|
|
|
50340A |
|
PT |
|
|
|
|
|
24/FEB/2017 |
|
50340A |
|
SE |
|
[*****] |
|
[*****] |
|
18/MAR/2011 |
|
50340A |
|
SE |
|
|
|
[*****] |
|
18/MAR/2016 |
|
50340A |
|
US |
|
|
|
[*****] |
|
09/NOV/2016 |
|
50340A |
|
US |
|
|
|
[*****] |
|
19/MAR/2011 |
|
50340A |
|
US |
|
[*****] |
|
|
|
19/MAR/2011 |
|
50340A |
|
US |
|
|
|
|
|
|
|
50340A |
|
US |
|
|
|
|
|
|
|
50340A |
|
US |
|
|
|
|
|
|
|
50351A |
|
DE |
|
[*****] |
|
[*****] |
|
05/APR/2011 |
|
50351A |
|
FR |
|
[*****] |
|
[*****] |
|
05/APR/2011 |
|
50351A |
|
GB |
|
[*****] |
|
[*****] |
|
05/APR/2011 |
|
50351A |
|
IE |
|
|
|
[*****] |
|
08/APR/2011 |
|
50351A |
|
IT |
|
[*****] |
|
[*****] |
|
05/APR/2011 |
|
50351A |
|
JP |
|
|
|
[*****] |
|
04/APR/2011 |
|
50351A |
|
NO |
|
|
|
[*****] |
|
05/APR/2011 |
|
50351A |
|
US |
|
|
|
[*****] |
|
12/JAN/2016 |
|
50351A |
|
US |
|
|
|
[*****] |
|
08/APR/2011 |
|
50351A |
|
US |
|
|
|
[*****] |
|
01/DEC/2015 |
|
50351A |
|
US |
|
|
|
|
|
08/APR/2011 |
|
50351A |
|
US |
|
|
|
|
|
|
45
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
50351A |
|
US |
|
|
|
|
|
08/APR/2011 |
|
50384A |
|
IE |
|
|
|
[*****] |
|
08/NOV/2011 |
|
50384A |
|
AT |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
BE |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
CH |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
DE |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
DK |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
ES |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
FR |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
GB |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
GR |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
IT |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
JP |
|
|
|
[*****] |
|
|
|
50384A |
|
LU |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
NL |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
PT |
|
|
|
[*****] |
|
19/JAN/2014 |
|
50384A |
|
SE |
|
[*****] |
|
[*****] |
|
07/NOV/2011 |
|
50384A |
|
US |
|
|
|
[*****] |
|
08/NOV/2011 |
|
50396B |
|
CA |
|
|
|
|
|
04/DEC/2012 |
|
50396B |
|
CZ |
|
|
|
[*****] |
|
04/DEC/2012 |
|
50396B |
|
DE |
|
[*****] |
|
|
|
06/DEC/2011 |
|
50396B |
|
EP |
|
[*****] |
|
[*****] |
|
03/DEC/2012 |
|
50396B |
|
HU |
|
|
|
|
|
04/DEC/2012 |
|
50396B |
|
IL |
|
[*****] |
|
[*****] |
|
06/DEC/2012 |
|
50396B |
|
JP |
|
|
|
|
|
07/DEC/2012 |
|
50396B |
|
NO |
|
|
|
[*****] |
|
04/DEC/2012 |
|
50396B |
|
NO |
|
|
|
[*****] |
|
04/DEC/2012 |
|
50396B |
|
NO |
|
|
|
[*****] |
|
04/DEC/2012 |
|
50396B |
|
NO |
|
|
|
[*****] |
|
04/DEC/2012 |
|
50396B |
|
NO |
|
|
|
[*****] |
|
04/DEC/2012 |
|
50396B |
|
SK |
|
|
|
[*****] |
|
04/DEC/2012 |
|
50396B |
|
US |
|
|
|
[*****] |
|
06/DEC/2012 |
|
50396B |
|
US |
|
|
|
|
|
|
|
50396B |
|
AT |
|
|
|
[*****] |
|
03/DEC/2012 |
|
50396B |
|
BE |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
DK |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
FR |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
LU |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
NL |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
ES |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
CH |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
GR |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
GB |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
SE |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
PT |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
MC |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
IT |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
IE |
|
|
|
|
|
03/DEC/2012 |
|
50396B |
|
DE |
|
|
|
[*****] |
|
03/DEC/2012 |
46
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
50449A |
|
AT |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
AU |
|
[*****] |
|
[*****] |
|
11/MAY/2012 |
|
50449A |
|
BE |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
CA |
|
|
|
[*****] |
|
13/MAY/2012 |
|
50449A |
|
CH |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
DE |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
DK |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
ES |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
FR |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
GB |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
GR |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
IE |
|
|
|
[*****] |
|
19/MAY/2012 |
|
50449A |
|
IL |
|
|
|
[*****] |
|
20/MAY/2012 |
|
50449A |
|
IT |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
JP |
|
|
|
[*****] |
|
28/MAY/2012 |
|
50449A |
|
LU |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
MC |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
NL |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
NO |
|
|
|
[*****] |
|
05/MAY/2012 |
|
50449A |
|
NZ |
|
[*****] |
|
[*****] |
|
08/MAY/2012 |
|
50449A |
|
PT |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
SE |
|
[*****] |
|
[*****] |
|
13/APR/2012 |
|
50449A |
|
US |
|
|
|
[*****] |
|
27/JUN/2012 |
|
50449A |
|
ZA |
|
|
|
[*****] |
|
07/MAY/2012 |
|
50479A |
|
AT |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
BE |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
CA |
|
|
|
|
|
28/MAY/2013 |
|
50479A |
|
CH |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
CZ |
|
|
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
DE |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
DE |
|
[*****] |
|
[*****] |
|
04/JUN/2012 |
|
50479A |
|
DK |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
ES |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
FR |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
GB |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
GR |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
HU |
|
|
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
IE |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
IL |
|
|
|
[*****] |
|
25/MAY/2013 |
|
50479A |
|
IT |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
JP |
|
|
|
|
|
28/MAY/2013 |
|
50479A |
|
KR |
|
|
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
LU |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
MC |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
NL |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
NO |
|
|
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
PT |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
SE |
|
[*****] |
|
[*****] |
|
28/MAY/2013 |
|
50479A |
|
SK |
|
|
|
[*****] |
|
28/MAY/2013 |
47
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
50479A |
|
US |
|
|
|
[*****] |
|
07/DEC/2012 |
|
50479A |
|
US |
|
|
|
|
|
|
|
50580A |
|
CA |
|
|
|
|
|
28/SEP/2013 |
|
50580A |
|
DE |
|
|
|
|
|
28/SEP/2012 |
|
50580A |
|
EP |
|
|
|
|
|
28/SEP/2013 |
|
50580A |
|
JP |
|
|
|
|
|
28/SEP/2013 |
|
50580A |
|
NO |
|
|
|
[*****] |
|
28/SEP/2013 |
|
50580A |
|
US |
|
|
|
[*****] |
|
15/DEC/2015 |
|
50580A |
|
ZA |
|
|
|
[*****] |
|
28/SEP/2013 |
|
50658A |
|
AT |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
AU |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
BE |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
CA |
|
|
|
|
|
08/JAN/2014 |
|
50658A |
|
CH |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
CN |
|
[*****] |
|
[*****] |
|
24/JAN/2014 |
|
50658A |
|
DE |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
DK |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
ES |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
FR |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
GB |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
GR |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
HU |
|
|
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
ID |
|
[*****] |
|
[*****] |
|
10/MAR/2014 |
|
50658A |
|
IE |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
IL |
|
|
|
[*****] |
|
16/JAN/2014 |
|
50658A |
|
IT |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
JP |
|
|
|
|
|
08/JAN/2014 |
|
50658A |
|
KR |
|
|
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
LU |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
MC |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
MY |
|
|
|
[*****] |
|
31/JUL/2015 |
|
50658A |
|
NL |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
NO |
|
|
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
NZ |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
PT |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
SE |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50658A |
|
TH |
|
|
|
|
|
24/JAN/2014 |
|
50658A |
|
TW |
|
[*****] |
|
[*****] |
|
11/MAR/2014 |
|
50658A |
|
US |
|
|
|
[*****] |
|
05/AUG/2014 |
|
50658A |
|
ZA |
|
|
|
[*****] |
|
25/JAN/2014 |
|
50659A |
|
AU |
|
|
|
|
|
10/NOV/2014 |
|
50659A |
|
KR |
|
|
|
|
|
10/NOV/2014 |
|
50659A |
|
NO |
|
|
|
|
|
10/NOV/2014 |
|
50659A |
|
NZ |
|
|
|
|
|
10/NOV/2014 |
|
50735A |
|
AT |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
BE |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
CA |
|
|
|
|
|
04/NOV/2013 |
|
50735A |
|
CH |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
CZ |
|
|
|
[*****] |
|
05/NOV/2013 |
48
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
50735A |
|
DE |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
DE |
|
[*****] |
|
[*****] |
|
06/NOV/2012 |
|
50735A |
|
DK |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
ES |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
FR |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
GB |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
GR |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
HU |
|
|
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
IE |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
IL |
|
|
|
[*****] |
|
25/OCT/2013 |
|
50735A |
|
IT |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
JP |
|
|
|
|
|
05/NOV/2013 |
|
50735A |
|
LU |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
MC |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
NL |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
NO |
|
|
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
PT |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
SE |
|
[*****] |
|
[*****] |
|
05/NOV/2013 |
|
50735A |
|
SK |
|
|
|
[*****] |
|
05/NOV/2013 |
|
50784A |
|
DE |
|
[*****] |
|
[*****] |
|
08/JAN/2014 |
|
50856A |
|
DE |
|
[*****] |
|
[*****] |
|
29/APR/2014 |
|
50856A |
|
DE |
|
|
|
[*****] |
|
28/MAY/2013 |
|
50856A |
|
JP |
|
|
|
|
|
|
|
50856A |
|
US |
|
|
|
[*****] |
|
05/MAY/2015 |
|
51041A |
|
AU |
|
|
|
[*****] |
|
02/DEC/2014 |
|
51041A |
|
DE |
|
[*****] |
|
[*****] |
|
02/DEC/2014 |
|
51041A |
|
FR |
|
[*****] |
|
[*****] |
|
02/DEC/2014 |
|
51041A |
|
GB |
|
[*****] |
|
[*****] |
|
02/DEC/2014 |
|
51041A |
|
IT |
|
[*****] |
|
[*****] |
|
02/DEC/2014 |
|
51041A |
|
JP |
|
|
|
|
|
|
|
51041A |
|
US |
|
|
|
[*****] |
|
02/JUN/2015 |
|
51081A |
|
CA |
|
|
|
|
|
28/JAN/2015 |
|
51081A |
|
JP |
|
|
|
|
|
28/JAN/2015 |
|
51081A |
|
US |
|
|
|
|
|
|
|
51108A |
|
AT |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
PT |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
NL |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
LU |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
GR |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
DK |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
GB |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
CH |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
SE |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
ES |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
MC |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
BE |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
DE |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
IE |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
IT |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
49
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51108A |
|
FR |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
AU |
|
|
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
DE |
|
|
|
|
|
07/JUL/2014 |
|
51108A |
|
EP |
|
[*****] |
|
[*****] |
|
04/JUL/2015 |
|
51108A |
|
JP |
|
|
|
|
|
|
|
51108A |
|
US |
|
|
|
|
|
06/JUN/2015 |
|
51108A |
|
US |
|
|
|
[*****] |
|
05/JUN/2015 |
|
51121A |
|
US |
|
|
|
[*****] |
|
05/JUN/2015 |
|
51121A |
|
US |
|
|
|
[*****] |
|
05/JUN/2015 |
|
51126A |
|
US |
|
|
|
[*****] |
|
02/JUN/2015 |
|
51130A |
|
CA |
|
|
|
|
|
28/MAY/2018 |
|
51130A |
|
DE |
|
[*****] |
|
[*****] |
|
02/JUN/2017 |
|
51130A |
|
EP |
|
|
|
[*****] |
|
28/MAY/2018 |
|
51130A |
|
IN |
|
|
|
|
|
28/MAY/2012 |
|
51130A |
|
JP |
|
|
|
|
|
28/MAY/2018 |
|
51130A |
|
MX |
|
|
|
|
|
28/MAY/2018 |
|
51130A |
|
NO |
|
|
|
[*****] |
|
28/MAY/2018 |
|
51130A |
|
TW |
|
[*****] |
|
[*****] |
|
01/JUN/2018 |
|
51130A |
|
US |
|
|
|
[*****] |
|
02/JUN/2018 |
|
51130A |
|
WO |
|
[*****] |
|
|
|
|
|
51130A |
|
ZA |
|
|
|
[*****] |
|
02/JUN/2018 |
|
51142A |
|
DE |
|
[*****] |
|
|
|
09/JUL/2016 |
|
51142A |
|
EP |
|
[*****] |
|
[*****] |
|
25/JUN/2017 |
|
51142A |
|
JP |
|
|
|
|
|
25/JUN/2017 |
|
51142A |
|
US |
|
|
|
[*****] |
|
25/JUN/2017 |
|
51142A |
|
WO |
|
[*****] |
|
|
|
|
|
51142A |
|
FR |
|
[*****] |
|
[*****] |
|
25/JUN/2017 |
|
51142A |
|
DE |
|
[*****] |
|
[*****] |
|
25/JUN/2017 |
|
51142A |
|
GB |
|
[*****] |
|
[*****] |
|
25/JUN/2017 |
|
51142A |
|
IT |
|
[*****] |
|
[*****] |
|
25/JUN/2017 |
|
51152A |
|
DE |
|
[*****] |
|
|
|
21/FEB/2015 |
|
51152A |
|
US |
|
|
|
[*****] |
|
07/JUN/2015 |
|
51155A |
|
AT |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
AU |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
BE |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
BY |
|
|
|
|
|
29/FEB/2016 |
|
51155A |
|
CA |
|
|
|
|
|
29/FEB/2016 |
|
51155A |
|
CH |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
CN |
|
[*****] |
|
|
|
29/FEB/2016 |
|
51155A |
|
DE |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
DE |
|
[*****] |
|
[*****] |
|
01/MAR/2015 |
|
51155A |
|
DK |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
ES |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
FI |
|
|
|
|
|
29/FEB/2016 |
|
51155A |
|
FR |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
GB |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
GR |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
HK |
|
[*****] |
|
|
|
29/FEB/2016 |
|
51155A |
|
HU |
|
|
|
[*****] |
|
29/FEB/2016 |
50
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51155A |
|
IE |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
IL |
|
|
|
[*****] |
|
20/FEB/2016 |
|
51155A |
|
IT |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
JP |
|
|
|
|
|
29/FEB/2016 |
|
51155A |
|
KR |
|
[*****] |
|
|
|
29/FEB/2016 |
|
51155A |
|
LU |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
MC |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
MX |
|
|
|
|
|
29/FEB/2016 |
|
51155A |
|
NL |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
NO |
|
|
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
NZ |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
PT |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
RU |
|
|
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
SE |
|
[*****] |
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
UA |
|
|
|
[*****] |
|
29/FEB/2016 |
|
51155A |
|
US |
|
|
|
|
|
29/FEB/2016 |
|
51155A |
|
VN |
|
|
|
[*****] |
|
01/MAR/2010 |
|
51155A |
|
ZA |
|
|
|
[*****] |
|
01/MAR/2016 |
|
51156A |
|
AT |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
AU |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
BE |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
BY |
|
|
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
CA |
|
|
|
|
|
29/JAN/2016 |
|
51156A |
|
CH |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
CN |
|
|
|
|
|
29/JAN/2016 |
|
51156A |
|
DE |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
DE |
|
[*****] |
|
[*****] |
|
27/JAN/2015 |
|
51156A |
|
DK |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
ES |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
FI |
|
|
|
|
|
29/JAN/2016 |
|
51156A |
|
FR |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
GB |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
GR |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
HK |
|
|
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
HU |
|
|
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
IE |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
IL |
|
|
|
[*****] |
|
26/JAN/2016 |
|
51156A |
|
IT |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
JP |
|
|
|
|
|
29/JAN/2016 |
|
51156A |
|
KR |
|
|
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
LU |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
MC |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
MX |
|
|
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
NL |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
NO |
|
|
|
|
|
29/JAN/2016 |
|
51156A |
|
NZ |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
PT |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
RU |
|
|
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
SE |
|
[*****] |
|
[*****] |
|
29/JAN/2016 |
51
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51156A |
|
UA |
|
|
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
US |
|
|
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
US |
|
|
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
VN |
|
|
|
[*****] |
|
29/JAN/2016 |
|
51156A |
|
ZA |
|
|
|
[*****] |
|
26/JAN/2016 |
|
51164A |
|
AU |
|
[*****] |
|
[*****] |
|
10/JUL/2015 |
|
51164A |
|
CA |
|
|
|
[*****] |
|
10/JUL/2015 |
|
51164A |
|
CN |
|
|
|
[*****] |
|
10/JUL/2015 |
|
51164A |
|
DE |
|
|
|
[*****] |
|
04/AUG/2014 |
|
51164A |
|
EP |
|
|
|
[*****] |
|
10/JUL/2015 |
|
51164A |
|
HU |
|
|
|
|
|
10/JUL/2015 |
|
51164A |
|
IL |
|
|
|
[*****] |
|
24/JUL/2015 |
|
51164A |
|
IL |
|
|
|
[*****] |
|
24/JUL/2015 |
|
51164A |
|
KR |
|
|
|
[*****] |
|
10/JUL/2015 |
|
51164A |
|
NO |
|
|
|
|
|
10/JUL/2015 |
|
51164A |
|
US |
|
|
|
|
|
10/JUL/2015 |
|
51164A |
|
US |
|
|
|
|
|
10/JUL/2015 |
|
51164A |
|
US |
|
|
|
|
|
10/JUL/2015 |
|
51164A |
|
US |
|
|
|
[*****] |
|
10/JUL/2015 |
|
51164A |
|
ZA |
|
|
|
[*****] |
|
19/JUL/2015 |
|
51201A |
|
CN |
|
[*****] |
|
|
|
08/MAY/2015 |
|
51201A |
|
CN |
|
[*****] |
|
|
|
08/MAY/2015 |
|
51201A |
|
CN |
|
[*****] |
|
[*****] |
|
08/MAY/2015 |
|
51201A |
|
HK |
|
[*****] |
|
|
|
08/MAY/2015 |
|
51201A |
|
HK |
|
[*****] |
|
|
|
08/MAY/2015 |
|
51229A |
|
US |
|
|
|
|
|
09/FEB/2016 |
|
51237A |
|
US |
|
|
|
[*****] |
|
07/JUN/2015 |
|
51246A |
|
CA |
|
|
|
|
|
18/NOV/2016 |
|
51246A |
|
JP |
|
|
|
|
|
18/NOV/2016 |
|
51246A |
|
NO |
|
|
|
|
|
18/NOV/2016 |
|
51246A |
|
US |
|
|
|
|
|
18/NOV/2016 |
|
51246A |
|
WO |
|
[*****] |
|
|
|
|
|
51263A |
|
EP |
|
|
|
|
|
26/APR/2016 |
|
51282A |
|
AU |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
AU |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
BG |
|
|
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
BR |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
BY |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
CA |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
CN |
|
[*****] |
|
|
|
20/JUN/2016 |
|
51282A |
|
CN |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
CZ |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
DE |
|
[*****] |
|
|
|
04/JUL/2015 |
|
51282A |
|
EP |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
HK |
|
[*****] |
|
|
|
20/JUN/2016 |
|
51282A |
|
IL |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
JP |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
KR |
|
[*****] |
|
|
|
20/JUN/2016 |
|
51282A |
|
MX |
|
|
|
|
|
20/JUN/2016 |
52
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51282A |
|
NO |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
NZ |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
PK |
|
|
|
|
|
04/FEB/2018 |
|
51282A |
|
PL |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
RU |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
SK |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
TW |
|
|
|
|
|
26/SEP/2011 |
|
51282A |
|
UA |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
US |
|
|
|
[*****] |
|
03/JUL/2016 |
|
51282A |
|
US |
|
|
|
|
|
03/JUL/2016 |
|
51282A |
|
US |
|
|
|
[*****] |
|
02/JUL/2016 |
|
51282A |
|
US |
|
|
|
[*****] |
|
03/JUL/2016 |
|
51282A |
|
US |
|
|
|
[*****] |
|
03/JUL/2016 |
|
51282A |
|
US |
|
[*****] |
|
|
|
03/JUL/2016 |
|
51282A |
|
US |
|
|
|
[*****] |
|
03/JUL/2016 |
|
51282A |
|
VN |
|
|
|
|
|
|
|
51282A |
|
VN |
|
|
|
|
|
04/JUL/2010 |
|
51282A |
|
ZA |
|
|
|
[*****] |
|
04/JUL/2016 |
|
51282A |
|
IL |
|
|
|
|
|
20/JUN/2016 |
|
51282A |
|
AT |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
CH |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
SE |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
ES |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
PT |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
MC |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
LU |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
IT |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
IE |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
GR |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
NL |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
FR |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
DK |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
GB |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
BE |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
DE |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51282A |
|
FI |
|
[*****] |
|
[*****] |
|
20/JUN/2016 |
|
51285A |
|
AT |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
AU |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
BE |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
CA |
|
|
|
|
|
26/FEB/2017 |
|
51285A |
|
CH |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
CN |
|
|
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
CZ |
|
|
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
DE |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
DE |
|
|
|
[*****] |
|
26/FEB/2016 |
|
51285A |
|
DK |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
ES |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
FI |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
FR |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
53
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51285A |
|
GB |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
GR |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
HK |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
IE |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
IL |
|
|
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
IT |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
JP |
|
|
|
|
|
26/FEB/2017 |
|
51285A |
|
KR |
|
|
|
|
|
26/FEB/2017 |
|
51285A |
|
LU |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
MC |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
NL |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
NO |
|
|
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
NZ |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
PL |
|
|
|
|
|
26/FEB/2017 |
|
51285A |
|
PT |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
SE |
|
[*****] |
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
SK |
|
|
|
[*****] |
|
26/FEB/2017 |
|
51285A |
|
US |
|
|
|
[*****] |
|
25/FEB/2017 |
|
51285A |
|
US |
|
|
|
|
|
16/DEC/1997 |
|
51285A |
|
WO |
|
[*****] |
|
|
|
|
|
51285A |
|
ZA |
|
|
|
[*****] |
|
26/FEB/2017 |
|
51315A |
|
AT |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
BE |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
CA |
|
|
|
|
|
20/DEC/2016 |
|
51315A |
|
CH |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
DE |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
DE |
|
[*****] |
|
[*****] |
|
04/JAN/2016 |
|
51315A |
|
DK |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
ES |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
FI |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
FR |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
GB |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
GR |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
IE |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
IT |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
JP |
|
|
|
|
|
20/DEC/2016 |
|
51315A |
|
LU |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
MC |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
NL |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
NO |
|
|
|
|
|
20/DEC/2016 |
|
51315A |
|
PT |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
SE |
|
[*****] |
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
US |
|
|
|
[*****] |
|
20/DEC/2016 |
|
51315A |
|
WO |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
BG |
|
|
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
BR |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
BY |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
CA |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
CN |
|
[*****] |
|
|
|
16/JAN/2017 |
54
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51322A |
|
CZ |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
DE |
|
[*****] |
|
|
|
19/JAN/2016 |
|
51322A |
|
EE |
|
[*****] |
|
|
|
16/JAN/2017 |
|
51322A |
|
EP |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
HK |
|
[*****] |
|
|
|
16/JAN/2017 |
|
51322A |
|
HU |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
IL |
|
|
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
IS |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
JP |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
KR |
|
[*****] |
|
|
|
16/JAN/2017 |
|
51322A |
|
MX |
|
|
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
NO |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
NZ |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
PK |
|
|
|
|
|
04/FEB/2018 |
|
51322A |
|
PL |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
RU |
|
[*****] |
|
|
|
16/JAN/2017 |
|
51322A |
|
SK |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
TW |
|
|
|
|
|
18/JAN/2012 |
|
51322A |
|
UA |
|
|
|
|
|
16/JAN/2017 |
|
51322A |
|
US |
|
|
|
[*****] |
|
17/JAN/2017 |
|
51322A |
|
US |
|
|
|
|
|
17/JAN/2017 |
|
51322A |
|
US |
|
|
|
|
|
17/JAN/2017 |
|
51322A |
|
US |
|
|
|
|
|
17/JAN/2017 |
|
51322A |
|
US |
|
|
|
|
|
28/FEB/1997 |
|
51322A |
|
VN |
|
|
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
WO |
|
[*****] |
|
|
|
|
|
51322A |
|
ZA |
|
|
|
[*****] |
|
17/JAN/2017 |
|
51322A |
|
LV |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
LT |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
RO |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
AT |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
FR |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
IT |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
GR |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
DE |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
BE |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
NL |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
PT |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
LU |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
IE |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
FI |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
DK |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
GB |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
CH |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
SE |
|
[*****] |
|
[*****] |
|
16/JAN/2017 |
|
51322A |
|
ES |
|
[*****] |
|
|
|
16/JAN/2017 |
|
51358A |
|
AU |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
AU |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
BG |
|
|
|
[*****] |
|
29/NOV/2016 |
55
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51358A |
|
BY |
|
|
|
|
|
29/NOV/2016 |
|
51358A |
|
CA |
|
|
|
|
|
29/NOV/2016 |
|
51358A |
|
CZ |
|
|
|
|
|
29/NOV/2016 |
|
51358A |
|
DE |
|
[*****] |
|
|
|
22/DEC/2015 |
|
51358A |
|
EP |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
IL |
|
|
|
|
|
29/NOV/2016 |
|
51358A |
|
IL |
|
|
|
|
|
29/NOV/2016 |
|
51358A |
|
JP |
|
|
|
|
|
29/NOV/2016 |
|
51358A |
|
KR |
|
[*****] |
|
|
|
29/NOV/2016 |
|
51358A |
|
MX |
|
|
|
|
|
29/NOV/2016 |
|
51358A |
|
NO |
|
|
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
NZ |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
PL |
|
|
|
|
|
29/NOV/2016 |
|
51358A |
|
RU |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
SK |
|
|
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
TW |
|
[*****] |
|
|
|
20/DEC/2011 |
|
51358A |
|
UA |
|
|
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
US |
|
|
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
US |
|
|
|
[*****] |
|
20/DEC/2016 |
|
51358A |
|
US |
|
|
|
|
|
05/JAN/1997 |
|
51358A |
|
VN |
|
|
|
|
|
|
|
51358A |
|
VN |
|
|
|
|
|
|
|
51358A |
|
WO |
|
[*****] |
|
|
|
|
|
51358A |
|
ZA |
|
|
|
[*****] |
|
20/DEC/2016 |
|
51358A |
|
AT |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
BE |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
DE |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
IE |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
LI |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
MC |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
PT |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
GB |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
CH |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
SE |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
ES |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
NL |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
LU |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
IT |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
GR |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
FR |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
FI |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51358A |
|
DK |
|
[*****] |
|
[*****] |
|
29/NOV/2016 |
|
51378A |
|
CA |
|
|
|
|
|
17/AUG/2018 |
|
51378A |
|
DE |
|
[*****] |
|
|
|
26/SEP/2017 |
|
51378A |
|
EP |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
JP |
|
|
|
|
|
17/AUG/2018 |
|
51378A |
|
NO |
|
|
|
|
|
17/AUG/2018 |
|
51378A |
|
US |
|
|
|
[*****] |
|
22/SEP/2018 |
|
51378A |
|
US |
|
|
|
|
|
06/OCT/1998 |
56
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51378A |
|
WO |
|
[*****] |
|
|
|
|
|
51378A |
|
AT |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
BE |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
CY |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
FI |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
IE |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
LU |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
DE |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
NL |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
FR |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
DK |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
GB |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
CH |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
SE |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
ES |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
PT |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
MC |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
IT |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51378A |
|
GR |
|
[*****] |
|
[*****] |
|
17/AUG/2018 |
|
51412B |
|
AU |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
BA |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
BG |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
BR |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
CA |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
CN |
|
[*****] |
|
|
|
19/JUN/2018 |
|
51412B |
|
CZ |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
EP |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
HK |
|
[*****] |
|
|
|
19/JUN/2018 |
|
51412B |
|
HU |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
IL |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
JP |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
KR |
|
[*****] |
|
|
|
19/JUN/2018 |
|
51412B |
|
MK |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
MX |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
NO |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
NZ |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
NZ |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
PL |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
RO |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
RU |
|
|
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
SI |
|
|
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
SK 2 |
|
|
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
TR |
|
|
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
UA |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
US |
|
[*****] |
|
|
|
19/JUN/2018 |
|
51412B |
|
WO |
|
[*****] |
|
|
|
|
|
51412B |
|
YU |
|
|
|
|
|
19/JUN/2018 |
|
51412B |
|
ZA |
|
|
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
DK |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
57
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51412B |
|
GB |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
CH |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
NL |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
FR |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
IT |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
|
51412B |
|
DE |
|
[*****] |
|
[*****] |
|
19/JUN/2018 |
|
51433A |
|
AR |
|
|
|
|
|
04/AUG/2017 |
|
51433A |
|
AT |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
AU |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
BE |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
CA |
|
|
|
|
|
29/JUL/2017 |
|
51433A |
|
CH |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
CN |
|
|
|
|
|
29/JUL/2017 |
|
51433A |
|
DE |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
DE |
|
|
|
[*****] |
|
29/JUL/2007 |
|
51433A |
|
DK |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
ES |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
FI |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
FR |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
GB |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
GR |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
HK |
|
[*****] |
|
|
|
29/JUL/2017 |
|
51433A |
|
HU |
|
|
|
|
|
29/JUL/2017 |
|
51433A |
|
IE |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
IL |
|
|
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
IT |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
JP |
|
|
|
|
|
29/JUL/2017 |
|
51433A |
|
KR |
|
[*****] |
|
|
|
29/JUL/2017 |
|
51433A |
|
LU |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
MC |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
MX |
|
|
|
|
|
29/JUL/2017 |
|
51433A |
|
NL |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
NO |
|
|
|
|
|
29/JUL/2017 |
|
51433A |
|
NZ |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
PT |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
SE |
|
[*****] |
|
[*****] |
|
29/JUL/2017 |
|
51433A |
|
TH |
|
[*****] |
|
|
|
04/AUG/2017 |
|
51433A |
|
TW |
|
|
|
|
|
05/AUG/2012 |
|
51433A |
|
US |
|
|
|
[*****] |
|
01/AUG/2017 |
|
51433A |
|
WO |
|
[*****] |
|
|
|
|
|
51433A |
|
ZA |
|
|
|
[*****] |
|
05/AUG/2017 |
|
51433A |
|
US |
|
|
|
|
|
01/AUG/2017 |
|
51437A |
|
AU |
|
[*****] |
|
[*****] |
|
26/NOV/2017 |
|
51437A |
|
CA |
|
|
|
|
|
26/NOV/2017 |
|
51437A |
|
CN |
|
[*****] |
|
[*****] |
|
26/NOV/2017 |
|
51437A |
|
DE |
|
[*****] |
|
|
|
04/DEC/2016 |
|
51437A |
|
EP |
|
[*****] |
|
|
|
26/NOV/2017 |
|
51437A |
|
HK |
|
[*****] |
|
|
|
26/NOV/2017 |
|
51437A |
|
IL |
|
|
|
|
|
26/NOV/2017 |
58
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51437A |
|
JP |
|
|
|
|
|
26/NOV/2017 |
|
51437A |
|
KR |
|
[*****] |
|
|
|
26/NOV/2017 |
|
51437A |
|
MX |
|
|
|
|
|
26/NOV/2017 |
|
51437A |
|
TW |
|
[*****] |
|
[*****] |
|
25/NOV/2017 |
|
51437A |
|
US |
|
|
|
[*****] |
|
02/DEC/2017 |
|
51437A |
|
WO |
|
[*****] |
|
|
|
|
|
51437A |
|
ZA |
|
|
|
[*****] |
|
04/DEC/2017 |
|
51457A |
|
DE |
|
[*****] |
|
|
|
04/DEC/2016 |
|
51457A |
|
EP |
|
[*****] |
|
|
|
26/NOV/2017 |
|
51457A |
|
JP |
|
|
|
|
|
26/NOV/2017 |
|
51457A |
|
NO |
|
|
|
[*****] |
|
26/NOV/2017 |
|
51457A |
|
TW |
|
[*****] |
|
[*****] |
|
25/NOV/2017 |
|
51457A |
|
US |
|
|
|
[*****] |
|
02/DEC/2017 |
|
51457A |
|
WO |
|
[*****] |
|
|
|
|
|
51457A |
|
ZA |
|
[*****] |
|
|
|
04/DEC/2017 |
|
51479A |
|
US |
|
|
|
|
|
08/JUL/1998 |
|
51502A |
|
DE |
|
[*****] |
|
|
|
03/JUL/2017 |
|
51502A |
|
EP |
|
[*****] |
|
|
|
28/MAY/2018 |
|
51502A |
|
JP |
|
|
|
|
|
28/MAY/2018 |
|
51502A |
|
TW |
|
[*****] |
|
|
|
02/JUL/2013 |
|
51502A |
|
US |
|
|
|
|
|
29/JUN/2018 |
|
51502A |
|
US |
|
[*****] |
|
|
|
29/JUN/2018 |
|
51502A |
|
US |
|
|
|
|
|
29/JUL/1998 |
|
51502A |
|
WO |
|
[*****] |
|
|
|
|
|
51502A |
|
ZA |
|
|
|
[*****] |
|
03/JUL/2018 |
|
51502A |
|
IN |
|
|
|
|
|
09/OCT/2022 |
|
51519A |
|
KP |
|
|
|
[*****] |
|
02/SEP/2013 |
|
51521A |
|
DE |
|
[*****] |
|
[*****] |
|
10/MAR/2020 |
|
51521A |
|
EP |
|
[*****] |
|
|
|
22/FEB/2021 |
|
51521A |
|
US |
|
[*****] |
|
|
|
08/MAR/2021 |
|
51521A |
|
US |
|
|
|
|
|
26/SEP/2001 |
|
51521A |
|
WO |
|
[*****] |
|
|
|
|
|
51521A |
|
JP |
|
|
|
|
|
22/FEB/2021 |
|
51521A |
|
NO |
|
|
|
|
|
22/FEB/2021 |
|
51538A |
|
US |
|
|
|
|
|
24/SEP/2018 |
|
51538A |
|
CA |
|
|
|
|
|
17/AUG/2018 |
|
51538A |
|
DE |
|
|
|
[*****] |
|
26/SEP/2017 |
|
51538A |
|
EP |
|
[*****] |
|
|
|
17/AUG/2018 |
|
51538A |
|
JP |
|
|
|
|
|
17/AUG/2018 |
|
51538A |
|
NO |
|
|
|
|
|
17/AUG/2018 |
|
51538A |
|
US |
|
|
|
[*****] |
|
24/SEP/2018 |
|
51538A |
|
US |
|
|
|
|
|
06/OCT/1998 |
|
51538A |
|
WO |
|
[*****] |
|
|
|
|
|
51545A |
|
AU |
|
|
|
|
|
15/MAR/2020 |
|
51545A |
|
CA |
|
|
|
|
|
15/MAR/2020 |
|
51545A |
|
CN |
|
|
|
|
|
15/MAR/2020 |
|
51545A |
|
DE |
|
|
|
[*****] |
|
22/MAR/2019 |
|
51545A |
|
EP |
|
[*****] |
|
|
|
15/MAR/2020 |
|
51545A |
|
HU |
|
|
|
|
|
15/MAR/2020 |
59
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51545A |
|
IL |
|
|
|
|
|
15/MAR/2020 |
|
51545A |
|
IN |
|
|
|
|
|
15/MAR/2014 |
|
51545A |
|
JP |
|
[*****] |
|
|
|
15/MAR/2020 |
|
51545A |
|
KR |
|
[*****] |
|
|
|
15/MAR/2020 |
|
51545A |
|
NO |
|
|
|
|
|
15/MAR/2020 |
|
51545A |
|
NZ |
|
|
|
|
|
15/MAR/2020 |
|
51545A |
|
US |
|
|
|
[*****] |
|
22/MAR/2020 |
|
51545A |
|
US |
|
|
|
|
|
09/APR/2000 |
|
51545A |
|
WO |
|
[*****] |
|
|
|
|
|
51545A |
|
ZA |
|
|
|
|
|
15/MAR/2020 |
|
51545A |
|
HK |
|
[*****] |
|
|
|
15/MAR/2020 |
|
51547A |
|
DE |
|
[*****] |
|
|
|
17/DEC/2017 |
|
51547A |
|
EP |
|
[*****] |
|
[*****] |
|
09/DEC/2018 |
|
51547A |
|
JP |
|
|
|
|
|
09/DEC/2018 |
|
51547A |
|
US |
|
[*****] |
|
|
|
17/DEC/2018 |
|
51547A |
|
US |
|
|
|
|
|
07/JAN/1999 |
|
51547A |
|
WO |
|
|
|
|
|
|
|
51549A |
|
WO |
|
[*****] |
|
|
|
|
|
51562A |
|
US |
|
|
|
|
|
03/DEC/1999 |
|
51562A |
|
WO |
|
[*****] |
|
|
|
|
|
51563A |
|
US |
|
|
|
|
|
03/DEC/1999 |
|
51563A |
|
WO |
|
[*****] |
|
|
|
|
|
51564A |
|
WO |
|
[*****] |
|
|
|
|
|
51590A |
|
DE |
|
[*****] |
|
|
|
03/APR/2018 |
|
51613A |
|
DE |
|
[*****] |
|
|
|
24/JUL/2018 |
|
51613A |
|
EP |
|
[*****] |
|
|
|
15/JUL/2019 |
|
51613A |
|
JP |
|
|
|
|
|
15/JUL/2019 |
|
51613A |
|
NO |
|
|
|
|
|
15/JUL/2019 |
|
51613A |
|
TW |
|
|
|
|
|
02/JUL/2014 |
|
51613A |
|
US |
|
[*****] |
|
|
|
23/JUL/2019 |
|
51613A |
|
US |
|
|
|
|
|
30/OCT/1999 |
|
51613A |
|
WO |
|
[*****] |
|
|
|
|
|
51614A |
|
DE |
|
|
|
[*****] |
|
22/SEP/2018 |
|
51614A |
|
EP |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
JP |
|
|
|
|
|
20/AUG/2019 |
|
51614A |
|
NO |
|
|
|
|
|
20/AUG/2019 |
|
51614A |
|
US |
|
|
|
[*****] |
|
21/SEP/2019 |
|
51614A |
|
US |
|
|
|
|
|
09/NOV/1999 |
|
51614A |
|
WO |
|
[*****] |
|
|
|
|
|
51614A |
|
AT |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
FI |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
NL |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
LU |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
DK |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
GB |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
CH |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
SE |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
ES |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
PT |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
60
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51614A |
|
MC |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
IT |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
IE |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
GR |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
DE |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
FR |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
CY |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51614A |
|
BE |
|
[*****] |
|
[*****] |
|
20/AUG/2019 |
|
51645A |
|
AU |
|
|
|
|
|
17/NOV/2019 |
|
51645A |
|
CA |
|
|
|
|
|
17/NOV/2019 |
|
51645A |
|
CN |
|
[*****] |
|
|
|
A 17/NOV/2019 |
|
51645A |
|
CZ |
|
|
|
|
|
17/NOV/2019 |
|
51645A |
|
DE |
|
|
|
[*****] |
|
02/DEC/2018 |
|
51645A |
|
EP |
|
[*****] |
|
|
|
17/NOV/2019 |
|
51645A |
|
HK |
|
[*****] |
|
|
|
17/NOV/2019 |
|
51645A |
|
IL |
|
|
|
|
|
17/NOV/2019 |
|
51645A |
|
JP |
|
|
|
|
|
17/NOV/2019 |
|
51645A |
|
KR |
|
[*****] |
|
|
|
17/NOV/2019 |
|
51645A |
|
NO |
|
|
|
|
|
17/NOV/2019 |
|
51645A |
|
NZ |
|
|
|
|
|
17/NOV/2019 |
|
51645A |
|
SK |
|
|
|
|
|
17/NOV/2019 |
|
51645A |
|
US |
|
|
|
[*****] |
|
01/DEC/2019 |
|
51645A |
|
US |
|
|
|
|
|
15/JAN/2000 |
|
51645A |
|
WO |
|
[*****] |
|
|
|
|
|
51645A |
|
ZA |
|
|
|
[*****] |
|
17/NOV/2019 |
|
51658A |
|
JP |
|
|
|
|
|
17/SEP/2018 |
|
51669A |
|
DE |
|
|
|
|
|
29/SEP/2019 |
|
51669A |
|
EP |
|
[*****] |
|
|
|
28/SEP/2020 |
|
51669A |
|
US |
|
|
|
|
|
29/SEP/2020 |
|
51669A |
|
US |
|
|
|
|
|
08/OCT/2000 |
|
51684A |
|
WO |
|
[*****] |
|
|
|
|
|
51729A |
|
DE |
|
[*****] |
|
|
|
29/SEP/2019 |
|
51729A |
|
EP |
|
[*****] |
|
|
|
28/SEP/2020 |
|
51729A |
|
US |
|
|
|
[*****] |
|
29/SEP/2020 |
|
51729A |
|
US |
|
|
|
|
|
08/OCT/2000 |
|
51729A |
|
US |
|
|
|
|
|
12/JUL/2022 |
|
51734A |
|
PE |
|
|
|
|
|
19/JUL/2022 |
|
51734A |
|
AR |
|
|
|
|
|
19/JUL/2022 |
|
51734A |
|
CL |
|
|
|
|
|
|
|
51734A |
|
DE |
|
|
|
[*****] |
|
20/JUL/2021 |
|
51734A |
|
TW |
|
|
|
|
|
19/JUL/2022 |
|
51734A |
|
US |
|
|
|
|
|
19/JUL/2022 |
|
51734A |
|
UY |
|
|
|
|
|
17/JUL/2022 |
|
51734A |
|
VE |
|
|
|
|
|
|
|
51734A |
|
WO |
|
[*****] |
|
|
|
|
|
51734B |
|
AR |
|
|
|
|
|
19/JUL/2022 |
|
51734B |
|
CL |
|
|
|
|
|
|
|
51734B |
|
DE |
|
|
|
[*****] |
|
20/JUL/2021 |
|
51734B |
|
TW |
|
|
|
|
|
19/JUL/2022 |
61
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51734B |
|
US |
|
|
|
|
|
19/JUL/2022 |
|
51734B |
|
VE |
|
|
|
|
|
|
|
51734B |
|
WO |
|
[*****] |
|
|
|
|
|
51734B |
|
UY |
|
|
|
|
|
17/JUL/2022 |
|
51734B |
|
PE |
|
|
|
|
|
19/JUL/2022 |
|
51735A |
|
US |
|
|
|
|
|
08/OCT/2000 |
|
51752A |
|
DE |
|
[*****] |
|
|
|
06/AUG/2019 |
|
51752A |
|
EP |
|
[*****] |
|
|
|
25/JUL/2020 |
|
51752A |
|
JP |
|
|
|
|
|
25/JUL/2020 |
|
51752A |
|
US |
|
|
|
|
|
04/AUG/2020 |
|
51752A |
|
US |
|
|
|
|
|
16/AUG/2000 |
|
51752A |
|
WO |
|
[*****] |
|
|
|
|
|
51760A |
|
AR |
|
|
|
|
|
10/AUG/2021 |
|
51760A |
|
CL |
|
|
|
|
|
|
|
51760A |
|
DE |
|
[*****] |
|
|
|
11/AUG/2020 |
|
51760A |
|
PH |
|
|
|
|
|
10/AUG/2021 |
|
51760A |
|
TH |
|
|
|
|
|
10/AUG/2021 |
|
51760A |
|
TW |
|
|
|
|
|
17/AUG/2016 |
|
51760A |
|
US |
|
|
|
|
|
10/AUG/2021 |
|
51760A |
|
US |
|
|
|
|
|
26/SEP/2001 |
|
51760A |
|
VE |
|
|
|
|
|
|
|
51760A |
|
WO |
|
[*****] |
|
|
|
|
|
51760A |
|
AU |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
BY |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
CA |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
HR |
|
|
|
|
|
|
|
51760A |
|
HU |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
IL |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
YU |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
UA |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
KR |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
ZA |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
SK |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
PL |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
NO |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
NZ |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
MX |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
JP |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
HK |
|
|
|
|
|
|
|
51760A |
|
EP |
|
[*****] |
|
|
|
23/JUL/2021 |
|
51760A |
|
RU |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
EE |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
BR |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
IN |
|
|
|
|
|
23/JUL/2015 |
|
51760A |
|
CZ |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
CN |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
CO |
|
|
|
|
|
23/JUL/2021 |
|
51760A |
|
BG |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
AU |
|
|
|
|
|
23/JUL/2021 |
62
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51761A |
|
BG |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
CN |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
BR |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
BY |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
HR |
|
|
|
|
|
|
|
51761A |
|
EE |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
UA |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
KR |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
SK |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
RU |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
PL |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
NZ |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
MX |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
JP |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
HU |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
YU |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
ZA |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
IN |
|
|
|
|
|
23/JUL/2015 |
|
51761A |
|
HK |
|
|
|
|
|
|
|
51761A |
|
NO |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
IL |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
CO |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
EP |
|
[*****] |
|
|
|
23/JUL/2021 |
|
51761A |
|
CZ |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
CA |
|
|
|
|
|
23/JUL/2021 |
|
51761A |
|
AR |
|
|
|
|
|
10/AUG/2021 |
|
51761A |
|
CL |
|
|
|
|
|
|
|
51761A |
|
DE |
|
|
|
[*****] |
|
11/AUG/2020 |
|
51761A |
|
PH |
|
|
|
|
|
10/AUG/2021 |
|
51761A |
|
TH |
|
|
|
|
|
10/AUG/2021 |
|
51761A |
|
TW |
|
|
|
|
|
17/AUG/2016 |
|
51761A |
|
US |
|
[*****] |
|
|
|
10/AUG/2021 |
|
51761A |
|
US |
|
|
|
|
|
26/SEP/2001 |
|
51761A |
|
VE |
|
|
|
|
|
|
|
51761A |
|
WO |
|
[*****] |
|
|
|
|
|
51762A |
|
AR |
|
|
|
|
|
10/AUG/2021 |
|
51762A |
|
CL |
|
|
|
|
|
|
|
51762A |
|
DE |
|
[*****] |
|
|
|
11/AUG/2020 |
|
51762A |
|
TW |
|
|
|
|
|
17/AUG/2016 |
|
51762A |
|
US |
|
[*****] |
|
|
|
10/AUG/2021 |
|
51762A |
|
US |
|
|
|
|
|
26/SEP/2001 |
|
51762A |
|
UY |
|
|
|
|
|
07/AUG/2021 |
|
51762A |
|
VE |
|
|
|
|
|
|
|
51762A |
|
WO |
|
[*****] |
|
|
|
|
|
51762A |
|
AU |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
BY |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
BG |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
CO |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
CZ |
|
|
|
|
|
23/JUL/2021 |
63
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51762A |
|
IN |
|
|
|
|
|
23/JUL/2015 |
|
51762A |
|
JP |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
EP |
|
[*****] |
|
|
|
23/JUL/2021 |
|
51762A |
|
YU |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
PL |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
NZ |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
MX |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
BR |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
NO |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
HK |
|
|
|
|
|
|
|
51762A |
|
RU |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
EE |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
CA |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
IL |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
HU |
|
|
|
|
|
23/JUL/2021 |
|
51762A |
|
HR |
|
|
|
|
|
|
|
51762A |
|
CN |
|
|
|
|
|
23/JUL/2021 |
|
51766A |
|
AE |
|
|
|
|
|
06/SEP/2015 |
|
51766A |
|
AT |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
AU |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
BE |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
BG |
|
[*****] |
|
|
|
06/SEP/2020 |
|
51766A |
|
BR |
|
[*****] |
|
|
|
06/SEP/2020 |
|
51766A |
|
BY |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
CA |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
CH |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
CN |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
CY |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
CZ |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
DE |
|
[*****] |
|
|
|
09/SEP/2019 |
|
51766A |
|
DE |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
DE |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
DK |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
EE |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
EP |
|
[*****] |
|
|
|
06/SEP/2020 |
|
51766A |
|
ES |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
FI |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
FR |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
GB |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
GR |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
HR |
|
|
|
|
|
|
|
51766A |
|
HU |
|
[*****] |
|
|
|
06/SEP/2020 |
|
51766A |
|
ID |
|
[*****] |
|
|
|
06/SEP/2020 |
|
51766A |
|
IE |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
IL |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
IN |
|
|
|
|
|
06/SEP/2014 |
|
51766A |
|
IT |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
JP |
|
[*****] |
|
|
|
06/SEP/2020 |
|
51766A |
|
KR |
|
[*****] |
|
|
|
06/SEP/2020 |
64
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51766A |
|
LU |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
MC |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
MX |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
NL |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
NO |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
NZ |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
PL |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
PT |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
RU |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
SE |
|
[*****] |
|
[*****] |
|
09/SEP/2019 |
|
51766A |
|
SK |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
TW |
|
|
|
|
|
28/SEP/2015 |
|
51766A |
|
UA |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
US |
|
|
|
|
|
15/SEP/2019 |
|
51766A |
|
US |
|
|
|
|
|
11/SEP/2020 |
|
51766A |
|
US |
|
|
|
|
|
|
|
51766A |
|
WO |
|
[*****] |
|
|
|
|
|
51766A |
|
YU |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
ZA |
|
|
|
|
|
06/SEP/2020 |
|
51766A |
|
HK |
|
|
|
|
|
|
|
51766A |
|
US |
|
|
|
|
|
11/SEP/2020 |
|
51768A |
|
EP |
|
|
|
|
|
16/JAN/2022 |
|
51768A |
|
DE |
|
[*****] |
|
[*****] |
|
26/JAN/2021 |
|
51768A |
|
US |
|
|
|
|
|
28/JAN/2022 |
|
51768A |
|
US |
|
|
|
|
|
13/FEB/2002 |
|
51768A |
|
WO |
|
[*****] |
|
|
|
|
|
51769A |
|
DE |
|
|
|
[*****] |
|
06/APR/2021 |
|
51769A |
|
US |
|
|
|
|
|
24/APR/2002 |
|
51772A |
|
JP |
|
|
|
|
|
18/MAR/2017 |
|
51780A |
|
JP |
|
|
|
|
|
15/OCT/2019 |
|
51800A |
|
DE |
|
|
|
[*****] |
|
13/JAN/2020 |
|
51800A |
|
US |
|
|
|
|
|
27/JAN/2001 |
|
51800A |
|
WO |
|
[*****] |
|
|
|
|
|
51832A |
|
DE |
|
|
|
|
|
20/DEC/2022 |
|
51834A |
|
EP |
|
|
|
|
|
05/DEC/2021 |
|
51834A |
|
AR |
|
|
|
|
|
14/DEC/2021 |
|
51834A |
|
CL |
|
|
|
|
|
|
|
51834A |
|
DE |
|
[*****] |
|
[*****] |
|
15/DEC/2020 |
|
51834A |
|
JO |
|
|
|
|
|
02/JUL/2022 |
|
51834A |
|
PE |
|
|
|
|
|
13/DEC/2021 |
|
51834A |
|
SA |
|
|
|
|
|
|
|
51834A |
|
TH |
|
|
|
|
|
14/DEC/2021 |
|
51834A |
|
TW |
|
|
|
|
|
07/NOV/2016 |
|
51834A |
|
US |
|
|
|
|
|
13/DEC/2021 |
|
51834A |
|
US |
|
|
|
|
|
28/DEC/2001 |
|
51834A |
|
UY |
|
|
|
|
|
05/DEC/2021 |
|
51834A |
|
VE |
|
|
|
|
|
|
|
51834A |
|
WO |
|
[*****] |
|
|
|
|
|
51954A |
|
DE |
|
[*****] |
|
|
|
15/SEP/2020 |
65
|
File number |
|
Country C |
|
Publication number |
|
Grant number |
|
Expiry |
|
51954A |
|
TW |
|
|
|
|
|
14/SEP/2016 |
|
51954A |
|
US |
|
|
|
|
|
14/SEP/2021 |
|
51954A |
|
US |
|
|
|
|
|
27/SEP/2001 |
|
51954A |
|
WO |
|
[*****] |
|
|
|
|
|
51954A |
|
EP |
|
|
|
|
|
05/SEP/2021 |
|
51954A |
|
JP |
|
|
|
|
|
05/SEP/2021 |
|
51954A |
|
NO |
|
|
|
|
|
05/SEP/2021 |
|
52024A |
|
DE |
|
|
|
|
|
28/MAR/2022 |
|
52024A |
|
US |
|
|
|
|
|
|
|
52024A |
|
WO |
|
|
|
|
|
15/NOV/2022 |
|
52024A |
|
US |
|
|
|
|
|
|
|
52162A |
|
DE |
|
[*****] |
|
|
|
18/JUN/2021 |
|
52163A |
|
DE |
|
[*****] |
|
[*****] |
|
19/JUN/2021 |
|
52163A |
|
US |
|
|
|
|
|
19/JUN/2022 |
|
52163A |
|
WO |
|
[*****] |
|
|
|
|
|
52164A |
|
DE |
|
[*****] |
|
|
|
11/JUL/2021 |
|
52164A |
|
US |
|
|
|
|
|
11/JUL/2022 |
|
52164A |
|
US |
|
|
|
|
|
18/JUL/2002 |
|
52164A |
|
WO |
|
|
|
|
|
|
|
52165A |
|
AR |
|
|
|
|
|
10/JUL/2022 |
|
52165A |
|
CL |
|
|
|
|
|
|
|
52165A |
|
DE |
|
|
|
|
|
10/JUL/2021 |
|
52165A |
|
PE |
|
|
|
|
|
10/JUL/2022 |
|
52165A |
|
TW |
|
|
|
|
|
09/JUL/2022 |
|
52165A |
|
US |
|
|
|
|
|
07/OCT/2022 |
|
52165A |
|
US |
|
|
|
|
|
19/JUL/2002 |
|
52165A |
|
VE |
|
|
|
|
|
|
|
52165A |
|
WO |
|
[*****] |
|
|
|
|
|
52165A |
|
UY |
|
|
|
|
|
28/JUN/2022 |
|
52207A |
|
US |
|
|
|
|
|
22/OCT/2002 |
|
52231A |
|
DE |
|
|
|
|
|
03/APR/2023 |
|
52231A |
|
US |
|
|
|
|
|
|
|
52307A |
|
US |
|
|
|
|
|
16/JUL/2003 |
|
52307A |
|
DE |
|
|
|
|
|
10/JUL/2022 |
|
52308A |
|
DE |
|
|
|
|
|
13/DEC/2022 |
|
52308A |
|
US |
|
|
|
|
|
12/FEB/2004 |
|
52309A |
|
DE |
|
|
|
|
|
19/FEB/2023 |
|
52309A |
|
US |
|
|
|
|
|
06/MAR/2004 |
|
52335A |
|
DE |
|
|
|
|
|
03/APR/2023 |
|
52335A |
|
US |
|
|
|
|
|
11/APR/2004 |
|
53061A |
|
DE |
|
|
|
|
|
04/FEB/2023 |
|
53061A |
|
US |
|
|
|
|
|
12/FEB/2004 |
|
53063A |
|
DE |
|
|
|
|
|
03/APR/2023 |
|
53063A |
|
US |
|
|
|
|
|
|
|
53072A |
|
DE |
|
|
|
|
|
04/FEB/2023 |
|
53072A |
|
US |
|
|
|
|
|
12/FEB/2004 |
66
Lead Compound Criteria for a Small Molecule
In general, these are not “exclusion criteria” but are intended to provide the project team with a clear set of optimization variables that are the basis for the decision-making process and will be investigated in the lead compound optimization phase of the project.
Target:
The target has been validated [*****], and [*****], etc.)
Approaches without defined target:
For compounds [*****] an [*****] of [*****] in [*****] the [*****] of [*****] to [*****]. If possible, [*****].
The lead compound:
• Has [*****], i.e., [*****] and [*****] the [*****].
• Has shown [*****].
• For projects with a [*****], the [*****] at [*****]
• For projects [*****], the [*****] at [*****].
• Has a [*****] plan. [*****].
• [*****] have been [*****].
• [*****]: [*****] using [*****] as well as [*****].
• [*****]: [*****], [*****] and [*****].
• If [*****], an [*****] of the [*****] is [*****].
• [*****] for [*****] has been [*****].
• [*****] such as [*****] as well as [*****].
• Allows for [*****].
Biological screening models
If possible, the [*****] and [*****] should have been [*****] or [*****] in the [*****]. If [*****] these should also [*****]. The [*****] should be [*****], allow [*****] [*****] and be [*****] The [*****] should have [*****] or [*****]. In particular, the [*****] for [*****] If available, [*****] should be included in the [*****].
Extract from:
[*****]
67
Criteria needed to make a Development Candidate decision
The development candidate decision [*****] [*****] resulting in the [*****]
The development candidate compound should fulfill the criteria listed below, which should serve as reference points rather than as strict rules: there will be cases where some criteria are not applicable or where deviations are justified. In general, the following criteria should be met:
• [*****]
• [*****] and expected [*****]
• [*****] on third party [*****]
• [*****], [*****] and [*****] for the [*****] in [*****]
• if possible, information available on [*****] with [*****] and [*****]
• appropriate [*****] [*****] relevant to the [*****] at [*****], where [*****] and [*****]
• expectation of [*****] for the [*****] based on [*****] and [*****])
• expectation of [*****] in relation to [*****] for the [*****]
Extract from :
[*****]
68
